UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark one)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from___ to___

Commission file number: 001-39388

Berkeley Lights, Inc.

(Exact name of registrant as specified in its charter)


Delaware			35-2415390
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

5858 Horton Street, Suite 320

Emeryville, California 94608

(Address of principal executive offices) (Zip code)

(510) 858-2855

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, $0.00005 par value

BLI

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Table of Contents

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~July 31,~~September 30, 2022 ~~68,283,926~~, 68,574,957 shares of the registrant’s common stock, $0.00005 par value per share, were outstanding.

Table of Contents

BERKELEY LIGHTS, INC.

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED ~~JUNE~~SEPTEMBER 30, 2022

Table of Contents


		Page(s)

Part I.	Financial Information	1

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets as of ~~June~~September 30, ~~202~~2 2022 and December 31, ~~202~~12021	1

	Condensed Consolidated Statements of Operations for the three and ~~six~~nine months ended ~~June~~September 30, ~~202~~2 2022 and ~~202~~12021	2

	Condensed Consolidated Statements of Comprehensive Loss for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021	3

	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and ~~six~~ nine months ended ~~June~~September 30, ~~202~~2 2022 and ~~202~~12021	4

	Condensed Consolidated Statements of Cash Flows for the ~~six~~nine months ended ~~June~~September 30, ~~202~~2 2022 and ~~202~~12021	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2325

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	38

Item 4.	Controls and Procedures	38

Part II.	Other Information	40

Item 1.	Legal Proceedings	40

Item 1A.	Risk Factors	40

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4042

Item 3.	Defaults Upon Senior Securities	4142

Item 4.	Mine Safety Disclosures	4142

Item 5	Other Information	4142

Item 6.	Exhibits	4243

	Signatures	4344

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited).

Berkeley Lights, Inc.

Condensed Consolidated Balance Sheets

June 30,
2022 December 31,
2021
(In thousands, except share and per share data) (unaudited)
Assets
Current assets:
Cash and cash equivalents $ 143,024 $ 178,096
Short-term marketable securities 9,361 —
Trade accounts receivable 13,815 25,942
Inventory 15,664 14,547
Prepaid expenses and other current assets 10,606 11,985
Total current assets 192,470 230,570
Restricted cash — 270
Property and equipment, net 29,317 27,992
Operating lease right-of-use assets 24,522 26,060
Other assets 2,397 2,361
Total assets $ 248,706 $ 287,253
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable $ 8,499 $ 8,198
Accrued expenses and other current liabilities 11,945 12,425
Deferred revenue 8,694 12,128
Total current liabilities 29,138 32,751
Notes payable 19,794 19,762
Deferred revenue, net of current portion 1,221 2,187
Lease liability, long-term 24,137 24,337
Total liabilities 74,290 79,037
Commitments and contingencies (Note 14) 0 0
Stockholders’ equity:
Common stock, $0.00005 par value. Authorized 300,000,000 shares at June 30, 2022 and December 31, 2021; issued and outstanding 68,273,932 and 67,595,535 shares at June 30, 2022 and December 31, 2021, respectively 4 4
Additional paid-in capital 485,212 471,820
Accumulated deficit (310,781) (263,608)
Accumulated other comprehensive loss (19) —
Total stockholders’ equity 174,416 208,216
Total liabilities and stockholders’ equity $ 248,706 $ 287,253
(Unaudited)


	September 30, 2022		December 31, 2021
(In thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents	$	120,640	$	178,096
Short-term marketable securities	14,075		—
Trade accounts receivable	20,255		25,942
Inventory	15,706		14,547
Prepaid expenses and other current assets	10,285		11,985
Total current assets	180,961		230,570
Restricted cash	—		270
Property and equipment, net	27,704		27,992
Operating lease right-of-use assets	24,118		26,060
Other assets	2,101		2,361
Total assets	$	234,884	$	287,253
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable	$	7,921	$	8,198
Accrued expenses and other current liabilities	16,243		12,425
Current portion of notes payable	2,483		—
Deferred revenue	7,733		12,128
Total current liabilities	34,380		32,751
Notes payable	17,327		19,762
Deferred revenue, net of current portion	1,433		2,187
Lease liability, long-term	23,561		24,337

Total liabilities	76,701		79,037
Commitments and contingencies (Note 15)
Stockholders’ equity:

Common stock, $0.00005 par value. Authorized 300,000,000 shares at September 30, 2022 and December 31, 2021; issued and outstanding 68,574,957 and 67,595,535 shares at September 30, 2022 and December 31, 2021, respectively	4		4
Additional paid-in capital	490,544		471,820
Accumulated deficit	(332,347)		(263,608)
Accumulated other comprehensive loss	(18)		—
Total stockholders’ equity	158,183		208,216
Total liabilities and stockholders’ equity	$	234,884	$	287,253

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

Berkeley Lights, Inc.

Condensed Consolidated Statements of Operations (Unaudited)


		Three months ended June 30,				Six months ended June 30,					Three months ended September 30,				Nine months ended September 30,
(In thousands, except share and per share data)	(In thousands, except share and per share data)	2022		2021		2022		2021		(In thousands, except share and per share data)	2022		2021		2022		2021
Revenue:	Revenue:									Revenue:
Product revenue	Product revenue	$	9,468	$	13,021	$	19,242	$	26,554	Product revenue	$	15,946	$	16,704	$	35,188	$	43,258
Service revenue	Service revenue	9,682		6,229		20,114		11,324		Service revenue	5,452		7,620		25,566		18,944
Total revenue	Total revenue	19,150		19,250		39,356		37,878		Total revenue	21,398		24,324		60,754		62,202
Cost of sales:	Cost of sales:									Cost of sales:
Product cost of sales	Product cost of sales	2,614		3,332		5,309		7,035		Product cost of sales	4,602		4,797		9,911		11,832
Service cost of sales	Service cost of sales	3,610		3,190		7,294		5,664		Service cost of sales	1,771		4,114		9,065		9,778
Total cost of sales	Total cost of sales	6,224		6,522		12,603		12,699		Total cost of sales	6,373		8,911		18,976		21,610
Gross profit	Gross profit	12,926		12,728		26,753		25,179		Gross profit	15,025		15,413		41,778		40,592
Operating expenses:	Operating expenses:									Operating expenses:
Research and development	Research and development	18,178		13,535		35,751		26,562		Research and development	8,978		16,195		44,729		42,757
General and administrative		13,024		11,725		24,740		20,692
Sales and marketing		7,271		5,317		13,082		10,923
Selling, general and administrative										Selling, general and administrative	26,525		19,198		64,347		50,813
Restructuring										Restructuring	1,058		—		1,058		—
Total operating expenses	Total operating expenses	38,473		30,577		73,573		58,177		Total operating expenses	36,561		35,393		110,134		93,570
Loss from operations	Loss from operations	(25,547)		(17,849)		(46,820)		(32,998)		Loss from operations	(21,536)		(19,980)		(68,356)		(52,978)
Other income (expense):	Other income (expense):									Other income (expense):
Interest expense	Interest expense	(227)		(356)		(451)		(710)		Interest expense	(229)		(232)		(680)		(942)
Interest income	Interest income	53		43		87		109		Interest income	465		33		552		142
Other income (expense), net		(22)		34		35		53
Other expense, net										Other expense, net	(244)		(170)		(209)		(117)
Loss before income taxes	Loss before income taxes	(25,743)		(18,128)		(47,149)		(33,546)		Loss before income taxes	(21,544)		(20,349)		(68,693)		(53,895)
Provision for income taxes	Provision for income taxes	4		26		24		43		Provision for income taxes	22		54		46		97
Net loss	Net loss	$	(25,747)	$	(18,154)	$	(47,173)	$	(33,589)	Net loss	$	(21,566)	$	(20,403)	$	(68,739)	$	(53,992)

Net loss attributable to common stockholders per share, basic and diluted	Net loss attributable to common stockholders per share, basic and diluted	$	(0.38)	$	(0.27)	$	(0.70)	$	(0.51)	Net loss attributable to common stockholders per share, basic and diluted	$	(0.32)	$	(0.30)	$	(1.01)	$	(0.81)
Weighted-average shares used in calculating net loss per share, basic and diluted	Weighted-average shares used in calculating net loss per share, basic and diluted	67,985,664		66,790,755		67,842,372		66,029,307		Weighted-average shares used in calculating net loss per share, basic and diluted	68,384,115		67,213,282		68,024,937		66,428,303

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

Berkeley Lights, Inc.

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)


		Three months ended June 30,				Six months ended June 30,					Three months ended September 30,				Nine months ended September 30,
(In thousands)	(In thousands)	2022		2021		2022		2021		(In thousands)	2022		2021		2022		2021

Net loss	Net loss	$	(25,747)	$	(18,154)	$	(47,173)	$	(33,589)	Net loss	$	(21,566)	$	(20,403)	$	(68,739)	$	(53,992)
Other comprehensive loss:	Other comprehensive loss:									Other comprehensive loss:
Unrealized loss on marketable securities, net of tax		(19)		—		(19)		—
Other comprehensive loss:		(19)		—		(19)		—
Unrealized gain (loss) on marketable securities, net of tax										Unrealized gain (loss) on marketable securities, net of tax	1		—		(18)		—
Other comprehensive income (loss):										Other comprehensive income (loss):	1		—		(18)		—
Comprehensive loss	Comprehensive loss	$	(25,766)	$	(18,154)	$	(47,192)	$	(33,589)	Comprehensive loss	$	(21,565)	$	(20,403)	$	(68,757)	$	(53,992)

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

Berkeley Lights, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)

Three Months Ended June 30, 2022
Common Stock Additional
Paid-in
Capital Accumulated
Deficit Accumulated Other Comprehensive Loss Total
Stockholders'
Equity
(In thousands, except share data) Shares Amount
Balances at March 31, 2022 67,820,115 $ 4 $ 478,231 $ (285,034) $ — $ 193,201
Shares issued in connection with:
Exercise of stock options 181,013 — 354 — — 354
Vesting of restricted stock units 272,804 — — — — —
Stock-based compensation — — 6,627 — — 6,627
Other comprehensive loss — — — — (19) (19)
Net loss — — — (25,747) — (25,747)
Balances at June 30, 2022 68,273,932 $ 4 $ 485,212 $ (310,781) $ (19) $ 174,416
Three Months Ended June 30, 2021
Common Stock Additional
Paid-in
Capital Accumulated
Deficit Accumulated Other Comprehensive Loss Total
Stockholders'
Equity
(In thousands, except share data) Shares Amount
Balances at March 31, 2021 66,384,736 $ 4 $ 449,681 $ (207,319) $ — $ 242,366
Shares issued in connection with:
Exercise of stock options 644,610 — 1,985 — — 1,985
Vesting of restricted stock units 14,191 — — — — —
Stock-based compensation — — 5,642 — — 5,642
Net loss — — — (18,154) — (18,154)
Balances at June 30, 2021 67,043,537 $ 4 $ 457,308 $ (225,473) $ — $ 231,839


	Three Months Ended September 30, 2022
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at June 30, 2022	68,273,932	$	4	$	485,212	$	(310,781)	$	(19)	$	174,416
Shares issued in connection with:
Exercise of stock options	33,502	—		67		—		—		67
Vesting of restricted stock units	232,145	—		—		—		—		—
Employee stock purchase plan	35,378	—		109		—				109
Stock-based compensation	—	—		5,156		—		—		5,156
Other comprehensive gain	—	—		—		—		1		1
Net loss	—	—		—		(21,566)		—		(21,566)
Balances at September 30, 2022	68,574,957	$	4	$	490,544	$	(332,347)	$	(18)	$	158,183


	Three Months Ended September 30, 2021
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at June 30, 2021	67,043,537	$	4	$	457,308	$	(225,473)	$	—	$	231,839
Shares issued in connection with:
Exercise of stock options	345,126	—		1,327		—		—		1,327
Vesting of restricted stock units	19,928	—		—		—		—		—
Employee stock purchase plan	47,648	—		1,487		—		—		1,487
Stock-based compensation	—	—		5,935		—		—		5,935

Net loss	—	—		—		(20,403)		—		(20,403)
Balances at September 30, 2021	67,456,239	$	4	$	466,057	$	(245,876)	$	—	$	220,185

Table of Contents

Six Months Ended June 30, 2022
Common Stock Additional
Paid-in
Capital Accumulated
Deficit Accumulated Other Comprehensive Loss Total
Stockholders'
Equity
(In thousands, except share data) Shares Amount
Balances at December 31, 2021 67,595,535 $ 4 $ 471,820 $ (263,608) $ — $ 208,216
Shares issued in connection with:
Exercise of stock options 262,667 — 766 — — 766
Vesting of restricted stock units 300,384 — — — — —
Employee stock purchase plan 115,346 — 610 — — 610
Stock-based compensation — — 12,016 — — 12,016
Other comprehensive loss — — — — (19) (19)
Net loss —�� — — (47,173) — (47,173)
Balances at June 30, 2022 68,273,932 $ 4 $ 485,212 $ (310,781) $ (19) $ 174,416
Six Months Ended June 30, 2021
Common Stock Additional
Paid-in
Capital Accumulated
Deficit Accumulated Other Comprehensive Loss Total
Stockholders'
Equity
(In thousands, except share data) Shares Amount
Balances at December 31, 2020 64,486,246 $ 3 $ 436,662 $ (191,884) $ — $ 244,781
Shares issued in connection with:
Exercise of stock options 2,422,740 1 8,346 — — 8,347
Vesting of restricted stock units 19,191 — — — — —
Employee stock purchase plan 115,360 2,157 — 2,157
Stock-based compensation — — 10,143 — — 10,143
Net loss — — — (33,589) — (33,589)
Balances at June 30, 2021 67,043,537 $ 4 $ 457,308 $ (225,473) $ — $ 231,839


	Nine Months Ended September 30, 2022
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at December 31, 2021	67,595,535	$	4	$	471,820	$	(263,608)	$	—	$	208,216
Shares issued in connection with:
Exercise of stock options	296,169	—		833		—		—		833
Vesting of restricted stock units	532,529	—		—		—		—		—

Employee stock purchase plan	150,724	—		719		—		—		719
Stock-based compensation	—	—		17,172		—		—		17,172
Other comprehensive loss	—	—		—		—		(18)		(18)
Net loss	—	—		—		(68,739)		—		(68,739)
Balances at September 30, 2022	68,574,957	$	4	$	490,544	$	(332,347)	$	(18)	$	158,183


	Nine Months Ended September 30, 2021
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at December 31, 2020	64,486,246	$	3	$	436,662	$	(191,884)	$	—	$	244,781
Shares issued in connection with:
Exercise of stock options	2,767,866	1		9,673		—		—		9,674
Vesting of restricted stock units	39,119	—		—		—		—		—
Employee stock purchase plan	163,008			3,644				—		3,644
Stock-based compensation	—	—		16,078		—		—		16,078

Net loss	—	—		—		(53,992)		—		(53,992)
Balances at September 30, 2021	67,456,239	$	4	$	466,057	$	(245,876)	$	—	$	220,185

See accompanying notes to these condensed consolidated financial statements.

Table of Contents

Berkeley Lights, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)


		Six months ended June 30,					Nine months ended September 30,
(In thousands)	(In thousands)	2022		2021		(In thousands)	2022		2021

Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net loss	Net loss	$	(47,173)	$	(33,589)	Net loss	$	(68,739)	$	(53,992)
Adjustments to reconcile net loss to cash used in operating activities:	Adjustments to reconcile net loss to cash used in operating activities:					Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	Depreciation	4,431		2,654		Depreciation	6,580		3,957
Stock-based compensation	Stock-based compensation	11,958		10,123		Stock-based compensation	17,139		16,085
Amortization of operating lease right-of-use assets	Amortization of operating lease right-of-use assets	1,538		994		Amortization of operating lease right-of-use assets	2,328		1,602
Non-cash interest and other expense related to debt and note receivable agreements	Non-cash interest and other expense related to debt and note receivable agreements	32		36		Non-cash interest and other expense related to debt and note receivable agreements	48		51
Provision for excess and obsolete inventory	Provision for excess and obsolete inventory	479		330		Provision for excess and obsolete inventory	512		431
Loss on disposal and impairment of property and equipment	Loss on disposal and impairment of property and equipment	27		31		Loss on disposal and impairment of property and equipment	48		61

Other non-cash	Other non-cash	271		—		Other non-cash	227		—

Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Trade accounts receivable	Trade accounts receivable	12,128		(6,820)		Trade accounts receivable	5,687		(11,773)
Inventory	Inventory	(1,539)		(5,710)		Inventory	(1,390)		(5,121)
Prepaid expenses, other current assets and other assets	Prepaid expenses, other current assets and other assets	1,340		(639)		Prepaid expenses, other current assets and other assets	1,956		(3,345)
Trade accounts payable	Trade accounts payable	1,000		4,512		Trade accounts payable	591		8,096
Deferred revenue	Deferred revenue	(4,400)		2,942		Deferred revenue	(5,149)		5,910
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	(585)		1,872		Accrued expenses and other current liabilities	3,523		806
Operating lease liabilities	Operating lease liabilities	(95)		(831)		Operating lease liabilities	(864)		(1,478)

Net cash used in operating activities	Net cash used in operating activities	(20,588)		(24,095)		Net cash used in operating activities	(37,503)		(38,710)
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchase of property and equipment	Purchase of property and equipment	(6,758)		(4,382)		Purchase of property and equipment	(7,732)		(10,715)
Purchase of marketable securities	Purchase of marketable securities	(9,372)		—		Purchase of marketable securities	(18,793)		—

Proceeds from maturities of marketable securities						Proceeds from maturities of marketable securities	4,750		—
Net cash used in investing activities	Net cash used in investing activities	(16,130)		(4,382)		Net cash used in investing activities	(21,775)		(10,715)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Payment of debt issuance costs	Payment of debt issuance costs	—		(358)		Payment of debt issuance costs	—		(300)
Proceeds from issuance of common stock upon exercise of stock options	Proceeds from issuance of common stock upon exercise of stock options	766		8,347		Proceeds from issuance of common stock upon exercise of stock options	833		9,674
Proceeds from issuance of common stock under employee stock purchase plan	Proceeds from issuance of common stock under employee stock purchase plan	610		2,157		Proceeds from issuance of common stock under employee stock purchase plan	719		3,644
Net cash provided by financing activities	Net cash provided by financing activities	1,376		10,146		Net cash provided by financing activities	1,552		13,018
Net decrease in cash and cash equivalents and restricted cash	Net decrease in cash and cash equivalents and restricted cash	(35,342)		(18,331)		Net decrease in cash and cash equivalents and restricted cash	(57,726)		(36,407)
Cash and cash equivalents and restricted cash at beginning of period	Cash and cash equivalents and restricted cash at beginning of period	178,366		233,678		Cash and cash equivalents and restricted cash at beginning of period	178,366		233,678
Cash and cash equivalents and restricted cash at end of period	Cash and cash equivalents and restricted cash at end of period	$	143,024	$	215,347	Cash and cash equivalents and restricted cash at end of period	$	120,640	$	197,271

See accompanying notes to these condensed consolidated financial statements.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(1)The Company and Basis of Presentation

Description of Business

Berkeley Lights, Inc. (the “Company” or “Berkeley Lights”) is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights’ platform is a fully integrated, end-to-end solution, comprised of advanced automation systems, proprietary consumables, including the Company’s OptoSelect chips and reagent kits, ~~advanced automation systems~~ and advanced application and workflow software.

Berkeley Lights and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America.

Liquidity

The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three and ~~six~~nine months ended ~~June~~September 30, 2022, the Company had a consolidated net loss of ~~$25.7~~$21.6 million and ~~$47.2~~$68.7 million, respectively, and as of ~~June~~September 30, 2022 had an accumulated deficit of ~~$310.8~~$332.3 million. ~~Unrestricted cash,~~Cash, cash equivalents and marketable securities was ~~$152.4~~$134.7 million at ~~June~~September 30, 2022. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash, cash equivalents and marketable securities balance as of ~~June~~September 30, 2022 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements.

Organizational and presentational changes

During the third quarter 2022, the Company made certain changes to its operating structure to align with its new business strategy. These changes included reorganizing the Company’s go-to-market efforts, the termination of approximately 12% of its workforce (see Note 12 to these condensed consolidated financial statements for additional information), and additional organizational changes.

As part of these changes, the Company’s “service center,” a team of scientists and engineers who perform services for both internal and external projects, is now part of the Company’s platform sales and support organization. The service center historically reported to the Company’s former Chief Product Officer.

As a result of these changes, the Company updated its classification of operating expenses as follows:

1. Expenses related to the termination of employees during the third quarter discussed above are classified in “Restructuring” within Operating Expenses.

2. The Company now discloses “Selling, general and administrative” expenses which includes expenses historically reported in “Sales and marketing” as well as “General and administrative” expenses. The Company has reclassified the prior period to conform to the current period presentation for this change.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

3. Expenses associated with the Company’s service center are no longer be classified as “Research and development” expenses, and instead are classified as “Selling, general and administrative” expenses on the Company’s condensed consolidated statements of operations as of the third quarter of 2022.

Service center expenses recorded in “Selling, general and administrative” during the three months ended September 30, 2022, were $4.7 million. Service center expenses recorded in “Research and development” during the six months ended June 30, 2022, were $9.7 million. Service center expenses recorded in “Research and development” during the three and nine months ended September 30, 2021, were $3.8 million and $7.8 million, respectively.

(2)Summary of Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission and have not materially changed during the ~~six~~nine months ended ~~June~~September 30, 2022, with the exception of the accounting policies as described further below.

Short-Term Marketable Securities

The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities within “current assets” on the Company’s condensed consolidated balance sheets. The Company records these securities at fair value and accounts for the net unrealized gains and losses related to them as part of “other comprehensive ~~loss”~~income (loss)” on its condensed consolidated statement of comprehensive loss. The Company records realized gains and losses on the sale of its marketable securities in “Other ~~income,~~expense, net” in its condensed consolidated statement of operations.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

At each reporting date, the Company performs an evaluation of impairment of its short-term available-for-sale marketable debt securities to determine if the fair value of its investment is less than its amortized cost basis. Impairment is assessed at the individual security level. Factors considered in determining whether an investment is impaired include the Company’s intent and ability to hold the investment until the recovery of its amortized cost basis, any historical failure of the issuer to make scheduled interest or principal payments, any change to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer’s industry, and any significant deterioration in economic conditions.

Stock-Based Compensation

The Company maintains an incentive compensation plan under which stock options and restricted stock units (“~~RSU”~~RSUs”) are granted to employees, non-employee consultants and ~~non-employee consultants.~~directors.

Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs based on the closing ~~value~~price of ~~its~~the Company’s common stock ~~price listed~~as reported by Nasdaq on ~~the Nasdaq at~~ the date of the grant.

The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The fair value of stock options and RSUs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.

Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis.

For performance stock options and ~~awards~~RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.

The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.

(3)Marketable Securities

Short-Term Marketable Securities

The Company invests in available-for-sale marketable debt securities consisting of commercial paper and U.S. government securities with contractual maturities due within one year. The Company did not hold any investments in marketable debt securities as of December 31, 2021.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

The following table summarizes the amortized costs and carrying value of the Company’s available-for-sale marketable debt securities, by major security type, as of ~~June~~September 30, 2022 (in thousands):

As of June 30, 2022
Amortized Cost Unrealized Gains Unrealized Losses Fair Value
Commercial paper $ 5,395 $ — $ (8) $ 5,387
U.S. government securities 3,982 — (8) 3,974
Total $ 9,377 $ — $ (16) $ 9,361


	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	6,133	$	—	$	(5)	$	6,128
U.S. agency securities	1,983		1		—		1,984
U.S. government securities	5,969		—		(6)		5,963
Total	$	14,085	$	1	$	(11)	$	14,075

At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of ~~June~~September 30, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of ~~June~~September 30, 2022.

(4)Significant Risks and Uncertainties Including Business and Credit Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company’s cash, cash equivalents and short-term available-for-sale marketable securities are held by large, credit worthy financial

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

institutions. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these ~~banks~~financial institutions may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash, cash equivalents and marketable securities.

The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At each of ~~June~~September 30, 2022 and December 31, 2021, the Company had not recorded any material allowance for doubtful accounts.

~~Most of the Company’s customers are located in the United States and Asia Pacific.~~ For the three months ended ~~June~~September 30, 2022, ~~three~~two customers accounted for ~~20%, 11%,~~26% and 10% of revenue. For the ~~six~~nine months ended ~~June 30.~~September 30, 2022, ~~three customers~~one customer accounted for ~~16%, 11% and 10%~~19% of revenue. For the three months ended ~~June~~September 30, 2021, four customers accounted for 16%, 15%, 10% and 10%, of revenue. For the nine months ended September 30, 2021, three customers accounted for ~~27%~~21%, ~~18% and 11%, of revenue. For the six months ended June 30, 2021, three customers accounted for 14%, 11%~~15% and 10% of revenue.

As of ~~June~~September 30, 2022, ~~three~~two customers comprised ~~27%, 12%~~30% and ~~11%~~14% of accounts receivable. As of December 31, 2021, three customers accounted for 15%, 11% and 11% of accounts receivable.

(5)Revenue From Contracts With Customers

The Company’s revenue consists of both product revenue and service revenue, which is generated through the following revenue streams: (i) platform, (ii) recurring, and (iii) partnerships.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~(5)Revenue From Contracts With Customers~~

~~Disaggregation of Revenue~~

The following ~~table depicts the disaggregation of revenue by type of customer or sales channel and market segment as defined by nature of workflows and activities~~tables provide an overview of the ~~end customer~~Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations (in thousands):

Income Statement Classification

Product or Service sold

Revenue Stream

Product revenue

Sale of advanced automation systems (Beacon and Lightning systems, Culture Station)

Platform

Software

Platform

Fixed term sales-type lease arrangements with qualified customers

Platform

Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)

Recurring

Consumables and reagent kits (e.g. OptoSelect chips)

Recurring

Service revenue

Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types

Partnerships

Application support, installation and training

Platform

Fixed fee extended warranty and service programs

Recurring

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
Type of Sales Channel
Direct sales channel $ 14,067 $ 10,103 $ 29,553 $ 20,542
Distributor channel 5,083 9,147 9,803 17,336
Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878
Market
Antibody therapeutics $ 12,984 $ 13,672 $ 27,209 $ 28,786
Synthetic biology 2,067 1,856 4,539 3,840
Agricultural biology 1,854 — 3,345 —
Gene therapy 2,028 2,058 3,802 3,283
Cell therapy 217 1,664 461 1,969
Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878
The following tables provide information by revenue stream for the periods presented:

Revenues by market are determined by the revenue associated with workflows that the Company’s customers are utilizing, primarily on the Company’s Beacon platform, or by the nature of the workflows that the Company is developing under strategic partnerships and services agreements.


	Three Months Ended September 30, 2022						Nine Months Ended September 30, 2022
(in thousands)	Product		Service		Total		Product		Service		Total
Platform	$	11,646	$	114	$	11,760	$	24,619	$	971	$	25,590
Recurring	4,300		2,724		7,024		10,569		7,827		18,396
Partnerships	—		2,614		2,614		—		16,768		16,768
Total revenue	$	15,946	$	5,452	$	21,398	$	35,188	$	25,566	$	60,754


	Three Months Ended September 30, 2021						Nine Months Ended September 30, 2021
(in thousands)	Product		Service		Total		Product		Service		Total
Platform	$	13,702	$	426	$	14,128	$	35,005	$	1,628	$	36,633
Recurring	3,002		1,731		4,733		8,253		4,820		13,073
Partnerships	—		5,463		5,463		—		12,496		12,496
Total revenue	$	16,704	$	7,620	$	24,324	$	43,258	$	18,944	$	62,202

Revenues by geographical markets are presented in Note 1617 to these condensed consolidated financial statements.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Performance Obligations

A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.

As of ~~June~~September 30, 2022, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year was ~~$6.4~~$4.3 million, which, to the extent invoiced, is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately ~~20%~~44% is expected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

Contract Balances

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Trade accounts receivable	Trade accounts receivable	$	13,815	$	25,942	Trade accounts receivable	$	20,255	$	25,942
Contract assets, which are included in “Prepaid expenses and other current assets”	Contract assets, which are included in “Prepaid expenses and other current assets”	$	3,765	$	1,736	Contract assets, which are included in “Prepaid expenses and other current assets”	$	1,302	$	1,736
Contract assets, long-term, which are included in “Other assets”	Contract assets, long-term, which are included in “Other assets”	$	996	$	1,070	Contract assets, long-term, which are included in “Other assets”	$	681	$	1,070
Deferred revenue (current)	Deferred revenue (current)	$	8,694	$	12,128	Deferred revenue (current)	$	7,733	$	12,128
Deferred revenue (non-current)	Deferred revenue (non-current)	$	1,221	$	2,187	Deferred revenue (non-current)	$	1,433	$	2,187

The contract liabilities of ~~$9.9~~$9.2 million and $14.3 million as of ~~June~~September 30, 2022 and December 31, 2021, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three and ~~six~~nine months ended ~~June~~September 30, 2022 included $~~2.7~~1.3 million and ~~$9.9~~$11.2 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2021.

Sales-type Lease Arrangements

The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three and ~~six~~nine months ended ~~June~~September 30, 2022, respectively, and ~~$1.0 million~~was none and $2.7 million for the three and ~~six~~nine months ended ~~June~~September 30, 2021, respectively.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of ~~June~~September 30, 2022 (in thousands):


Year ending December 31,	Year ending December 31,	Sales-Type Leases		Year ending December 31,	Sales-Type Leases
Remainder of 2022	Remainder of 2022	$	1,212	Remainder of 2022	$	1,101
2023	2023	445		2023	445
2024	2024	853		2024	445

2025				2025	407
Total undiscounted cash flows	Total undiscounted cash flows	2,510		Total undiscounted cash flows	2,398
Less: unearned income	Less: unearned income	305		Less: unearned income	327
Total amounts due from customers(1)	Total amounts due from customers(1)	$	2,205	Total amounts due from customers(1)	$	2,071

(1) Of the 2.1 million, $0.3 million is recorded in trade accounts receivable, with the remaining balance recorded in contract assets.

(6)

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

~~(6)~~ Balance Sheet Accounts

Inventory

The following table shows the components of inventory (in thousands):


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Raw materials	Raw materials	$	10,861	$	8,296	Raw materials	$	11,431	$	8,296
Finished goods	Finished goods	4,803		6,251		Finished goods	4,275		6,251
Total	Total	$	15,664	$	14,547	Total	$	15,706	$	14,547

Prepaid expenses and other current assets

The following table shows the components of prepaid expenses and other current assets (in thousands):


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Contract asset	Contract asset	$	3,765	$	1,736	Contract asset	$	1,302	$	1,736
Vendor deposits	Vendor deposits	2,679		2,802		Vendor deposits	2,528		2,802
Deferred costs	Deferred costs	537		561		Deferred costs	558		561
Prepaid insurance	Prepaid insurance	399		2,944		Prepaid insurance	2,414		2,944
Other (1)	Other (1)	3,226		3,942		Other (1)	3,483		3,942
Total	Total	$	10,606	$	11,985	Total	$	10,285	$	11,985

(1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Accrued expenses and other current liabilities

The following table shows the components of accrued expenses and other current liabilities (in thousands):


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Accrued payroll and employee related expenses	Accrued payroll and employee related expenses	$	6,400	$	6,757	Accrued payroll and employee related expenses	$	7,342	$	6,757
Lease liability – short-term	Lease liability – short-term	3,046		2,941		Lease liability – short-term	3,238		2,941
Accrued product warranty	Accrued product warranty	752		1,085		Accrued product warranty	766		1,085
Accrued legal expenses	Accrued legal expenses	1,087		504		Accrued legal expenses	3,473		504
Other (1)	Other (1)	660		1,138		Other (1)	1,424		1,138
Total	Total	$	11,945	$	12,425	Total	$	16,243	$	12,425

(1) Other includes ~~primarily~~ accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.

(7)Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The fair value of the Company’s assets and liabilities, including cash equivalents and marketable debt securities, are measured at fair value on a recurring basis. As of ~~June~~September 30, 2022 the Company held investments in securities classified as cash equivalents. The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of ~~June~~September 30, 2022 and December 31, 2021 approximate fair value due to their relatively short maturities.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):


		June 30, 2022		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			September 30, 2022		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents:	Cash equivalents:									Cash equivalents:
Money market funds	Money market funds	$	32,233	$	32,233	$	—	$	—	Money market funds	$	3,072	$	3,072	$	—	$	—
Commercial paper	Commercial paper	22,595		—		22,595		—		Commercial paper	37,435		—		37,435		—
U.S. agency securities										U.S. agency securities	4,979		—		4,979		—
U.S. government securities	U.S. government securities	5,986		—		5,986		—		U.S. government securities	10,979		—		10,979		—
Total cash equivalents	Total cash equivalents	60,814		32,233		28,581		—		Total cash equivalents	56,465		3,072		53,393		—

Debt securities, available for sale:	Debt securities, available for sale:									Debt securities, available for sale:
Commercial paper	Commercial paper	5,387		—		5,387		—		Commercial paper	6,128		—		6,128		—
U.S. agency securities										U.S. agency securities	1,984		—		1,984		—
U.S. government securities	U.S. government securities	3,974		—		3,974		—		U.S. government securities	5,963		—		5,963		—
Total debt securities, available for sale	Total debt securities, available for sale	9,361		—		9,361		—		Total debt securities, available for sale	14,075		—		14,075		—
Total assets measured at fair value	Total assets measured at fair value	$	70,175	$	32,233	$	37,942	$	—	Total assets measured at fair value	$	70,540	$	3,072	$	67,468	$	—

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)


	December 31, 2021		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)

Cash equivalents:
Money market funds	$	25,138	$	25,138	$	—	$	—
Total cash equivalents	$	25,138	$	25,138	$	—	$	—

The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):

June 30, 2022 December 31, 2021
Carrying
Value Fair Value Carrying
Value Fair Value
Long-term debt, including current maturities $ 19,794 $ 19,287 $ 19,762 $ 19,298


	September 30, 2022				December 31, 2021
	Carrying Value		Fair Value		Carrying Value		Fair Value

Long-term debt, including current maturities	$	19,810	$	19,279	$	19,762	$	19,298

The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.

The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

(8)Property and Equipment, net

Property and equipment, net comprised the following (in thousands):


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Equipment, tooling and molds	Equipment, tooling and molds	$	38,599	$	33,972	Equipment, tooling and molds	$	38,897	$	33,972
Computer software and equipment	Computer software and equipment	2,929		3,019		Computer software and equipment	2,733		3,019
Furniture, fixtures and other	Furniture, fixtures and other	1,957		1,891		Furniture, fixtures and other	2,020		1,891
Leasehold improvements	Leasehold improvements	10,820		6,105		Leasehold improvements	10,828		6,105
Construction in process	Construction in process	778		4,803		Construction in process	809		4,803
Total property and equipment	Total property and equipment	55,083		49,790		Total property and equipment	55,287		49,790
Less: Accumulated depreciation	Less: Accumulated depreciation	(25,766)		(21,798)		Less: Accumulated depreciation	(27,583)		(21,798)
Property and equipment, net	Property and equipment, net	$	29,317	$	27,992	Property and equipment, net	$	27,704	$	27,992

Total depreciation expense for the three and ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$2.5~~$2.2 million and ~~$4.4,~~$6.6 million, respectively. Total depreciation expense for three and ~~six~~nine months ended ~~June~~September 30, 2021 was ~~$1.4~~$1.3 million and ~~$2.7~~$4.0 million, respectively.

During the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 losses on the impairment and disposal of property and equipment ~~was~~were not material.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(9)Leases

The Company leases office, manufacturing, distribution and laboratory facilities in Emeryville, California under multiple operating leases. During the third quarter of 2021, the Company extended the term for its leases related to the facilities in Emeryville ~~and these leases will now expire in~~to 2029. Also, during the third quarter of 2021, the Company entered into a seven year lease of space for office and laboratory operations in Lexington, Massachusetts.

The Company also leases 2two facilities in Shanghai, China for office and laboratory facilities under operating lease agreements that were entered into in July 2020. These leases expire at various dates, the latest of which is August 2023.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

Future payments associated with the Company’s operating lease liabilities as of ~~June~~September 30, 2022 isare as follows (in thousands):


		Operating leases			Operating leases

Undiscounted lease payments for the year ending December 31,	Undiscounted lease payments for the year ending December 31,			Undiscounted lease payments for the year ending December 31,
Remainder of 2022	Remainder of 2022	$	2,101	Remainder of 2022	$	1,089
2023	2023	4,273		2023	4,418
2024	2024	4,355		2024	4,507
2025	2025	4,486		2025	4,524
2026	2026	4,621		2026	4,621
Thereafter	Thereafter	12,223		Thereafter	12,223
Total undiscounted lease payments	Total undiscounted lease payments	32,059		Total undiscounted lease payments	31,382
Less: implied interest	Less: implied interest	(4,811)		Less: implied interest	(4,518)
Less: tenant improvement allowances receivable	Less: tenant improvement allowances receivable	(65)		Less: tenant improvement allowances receivable	(65)
Present value of operating lease payments	Present value of operating lease payments	27,183		Present value of operating lease payments	26,799
Less: current portion (1)	Less: current portion (1)	(3,046)		Less: current portion (1)	(3,238)
Total long-term operating lease liabilities	Total long-term operating lease liabilities	$	24,137	Total long-term operating lease liabilities	$	23,561

(1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”

Rent expense for the three and ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$1.4~~$1.1 million and ~~$2.5~~$3.3 million, respectively. Rent expense for the three and ~~six~~nine months ended ~~June~~September 30, 2021 was ~~$0.9~~$1.0 million and ~~$1.7~~$2.7 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were ~~$1.0~~$0.8 million and ~~$1.8~~$2.3 million for the three and ~~six~~nine months ended ~~June~~September 30, 2022, respectively, including non-lease components such as common area maintenance fees. Variable lease payments for operating leases were $0.6 million and ~~$1.1~~$1.7 million for the three and ~~six~~nine months ended ~~June~~September 30, 2021, respectively, including non-lease components such as common area maintenance fees.

The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):


		Six months ended June 30, 2022		Six months ended June 30, 2021			Nine months ended September 30, 2022		Nine months ended September 30, 2021

Right-of-use assets obtained for new operating lease liabilities	Right-of-use assets obtained for new operating lease liabilities	$	—	$	—	Right-of-use assets obtained for new operating lease liabilities	$	386	$	3,348
Right-of-use assets obtained for new operating lease liabilities - Modification of existing leases						Right-of-use assets obtained for new operating lease liabilities - Modification of existing leases	$	—	$	8,320
Cash paid for amounts included in the measurement of lease liabilities	Cash paid for amounts included in the measurement of lease liabilities	$	1,070	$	796	Cash paid for amounts included in the measurement of lease liabilities	$	1,760	$	2,628

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following summarizes additional information related to operating leases:


		June 30, 2022		December 31, 2021			September 30, 2022		December 31, 2021

Weighted-average remaining lease term (years)	Weighted-average remaining lease term (years)	7.02		7.51		Weighted-average remaining lease term (years)	6.72		7.51
Weighted-average discount rate	Weighted-average discount rate	4.67	%	4.67	%	Weighted-average discount rate	4.67	%	4.67	%

The Company also enters into leasing transactions in which the Company is the lessor, which to date have been classified as sales-type leases. See Note 5 ofto these condensed consolidated financial statements for the related lease disclosures.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

(10)Notes Payable

On May 23, 2018, the Company entered into a Loan and Security Agreement with East West Bank (“EWB”) providing it the ability to borrow up to $20.0 million. The loan facility was fully drawn as of May 23, 2018.

On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (the “Agreement”) with EWB. Pursuant to the Agreement, EWB provided a $20.0 million term loan (the “Term Loan”) which was used to refinance the term loan outstanding under the Loan and Security Agreement dated May 23, 2018. The Term Loan matures in 48 months and bears a fixed interest rate of 4.17%. The Term Loan has an initial interest-only period of 24 months, which can be extended to up to 36 months based on the achievement of certain liquidity measures, and can be pre-paid without penalty at any time.

The Agreement grants EWB a security interest in and liens on all assets of the Company, excluding intellectual property, which is subject to a double negative pledge. In addition, certain other terms of the original agreements as previously in effect were amended by the Agreement, including certain financial covenants. The Amended and Restated Loan and Security Agreement was accounted for as a debt modification and the Company capitalized incremental debt issuance costs.

Furthermore, the Agreement also provided the Company with a new $10.0 million revolving credit (the “Revolving Line”), which bears interest on the outstanding daily balance thereof of 0.70% above the Prime Rate (as defined in the Agreement). No amounts were outstanding under the Revolving Line as of ~~June~~September 30, 2022.

The Agreement contains certain financial and non-financial covenants. As of ~~June~~September 30, 2022, the Company was in compliance with the terms and covenants of the Agreement.

The following is a schedule of payments due on notes payable as of ~~June~~September 30, 2022 (in thousands):


		June 30, 2022			September 30, 2022
Year Ending December 31:	Year Ending December 31:			Year Ending December 31:
Remainder of 2022	Remainder of 2022	$	426	Remainder of 2022	$	213
2023	2023	6,617		2023	6,617
2024	2024	10,406		2024	10,406
2025	2025	4,210		2025	4,210

Total payments due	Total payments due	21,659		Total payments due	21,446
Less:	Less:			Less:
Interest payments, loan discounts and financing costs	Interest payments, loan discounts and financing costs	(1,865)		Interest payments, loan discounts and financing costs	(1,636)
Current portion, less loan discounts and financing costs	Current portion, less loan discounts and financing costs	—		Current portion, less loan discounts and financing costs	(2,483)
Notes payable, net of current portion	Notes payable, net of current portion	$	19,794	Notes payable, net of current portion	$	17,327

Total interest cost incurred for the three and six months ended June 30, 2022 was $0.2 million and $0.5 million, respectively. Total interest cost incurred for the three and six months ended June 30, 2021 was $0.4 million and $0.7 million, respectively.

1617

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Total interest cost incurred for the three and nine months ended September 30, 2022 was $0.2 million and $0.7 million, respectively. Total interest cost incurred for the three and nine months ended September 30, 2021 was $0.2 million and $0.9 million, respectively.

(11)Stock Compensation Plans

Stock-based compensation

Stock-based compensation related to the ~~Company's~~Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands):


		Three months ended June 30,				Six months ended June 30,					Three months ended September 30,				Nine months ended September 30,
		2022		2021		2022		2021			2022		2021		2022		2021

Cost of sales	Cost of sales	$	68	$	63	$	119	$	105	Cost of sales	$	119	$	85	$	238	$	190
Research and development	Research and development	2,292		1,599		3,873		2,660		Research and development	1,264		1,508		5,137		4,168
General and administrative		2,318		2,497		4,529		3,869
Sales and marketing		1,887		1,470		3,437		3,489
Selling, general and administrative										Selling, general and administrative	3,798		4,369		11,764		11,727
Total stock-based compensation	Total stock-based compensation	$	6,565	$	5,629	$	11,958	$	10,123	Total stock-based compensation	$	5,181	$	5,962	$	17,139	$	16,085

Stock-based compensation capitalized in inventory was not material as of ~~June~~September 30, 2022 and December 31, 2021.

Option Repricing

On May 19, 2022, the Company’s Board of Directors elected to reprice all outstanding stock options granted to non-executive employees of the Company under the Berkeley Lights, Inc. 2020 Incentive Plan with a strike price above the closing price of the Company’s common stock as reported onby Nasdaq as of May 19, 2022. The new strike price for these repriced stock options is $4.91, which was the May 19, 2022 ~~(which was $4.91).~~closing price. There were no other modifications to these options, including vesting schedules. Options representing 763,307 underlying shares were included in this repricing and the total incremental expense associated with the modification of these options was $1.5 million, of which $0.5 million was recorded in the second quarter of ~~2022.~~2022 with the remaining to be recognized through February 22, 2026.

In addition, non-executive employees of the Company with outstanding options granted under the Berkeley Lights 2011 Equity Incentive Plan with a strike price above the closing price of the Company’s common stock as reported on Nasdaq as of May 19, 2022 were granted an RSU for every two stock options held with a strike price above the closing price as of May 19, 2022. These RSUs were granted on June 1, 2022 and vest in full on June 1, ~~2024.~~2024, subject to the employee’s continued service. An aggregate total of 353,625 RSUs were granted to such employees resulting in $1.5 million of compensation expense, of which approximately $55 thousand was recorded in the second quarter of ~~2022.~~2022 with the remaining to be recognized through June 1, 2024.

CEO Equity ~~Grant~~Grants

On March 10, 2022, the Company granted ~~the~~its newly appointed Chief Executive Officer ~~of the Company~~ 1,017,177 RSUs, 339,059 time-based stock options and 678,118 performance-based stock options (“PSOs”). The RSUs and time-based stock options vest quarterly over 3 years and the time-based stock options have a 10 year term.

The PSOs have a 7-year performance period, a 10-year term and vest based upon the achievement of certain market conditions and a continued service-based requirement. Market condition-related vesting is triggered based on the Company’s stock price reaching certain goals that range from 2two to 20 times the Company share price on the date of grant.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Although no ~~awards~~PSOs will vest until a market condition is satisfied, as of March 31, 2022, the Company began recording stock-based compensation expense for each vesting tranche of the PSOs based on the estimated achievement date of the specified stock price target. The valuation and probability of achievement for each tranche is determined using a Monte Carlo simulation. The same Monte Carlo simulation is used as the basis for determining the expected achievement date. As the probability of achievement is factored in as part of the Monte Carlo simulation, the expense for these tranches will be recognized concurrently over each tranche’s estimated achievement date even if

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

some or all of the ~~options~~PSOs never vest. If the related market condition for a tranche is achieved earlier than expected, all unamortized expense for such tranche will be recognized immediately. As of ~~June~~September 30, 2022, none of the PSOs had vested.

(12)Restructuring

On July 21, 2022, to improve efficiency and manage operating expenses, the Company terminated the employment of approximately 12% of total full-time employees. The Company incurred $1.1 million of employee severance and termination-related restructuring costs associated with this activity during the third quarter of 2022, and any additional costs associated with this reorganization will be recorded as restructuring expense when they are incurred.

Changes in the Company’s restructuring liability are set forth in the table below (in thousands):


	Employee severance and termination
Restructuring liability as of June 30, 2022	$	—
Restructuring charges	1,058
Cash paid	(748)
Restructuring liability as of September 30, 2022	$	310

Restructuring liabilities are included in accrued expenses and other current liabilities in the condensed consolidated balance sheet.

(13)Income Taxes

The Company’s provision for income taxes was ~~$4,000~~$22,000 and ~~$24,000,~~$46,000, respectively, for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and ~~$26,000~~$54,000 and ~~$43,000,~~$97,000, respectively, for the three and ~~six~~nine months ended ~~June~~September 30, 2021. For the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~(13)~~(14)Statements of Cash Flows

The supplemental cash flow information consists of the following (in thousands):


		Six months ended June 30,					Nine months ended September 30,
		2022		2021			2022		2021
Cash paid for interest	Cash paid for interest	$	278	$	681	Cash paid for interest	$	422	$	828
Cash paid for income taxes	Cash paid for income taxes	$	—	$	3	Cash paid for income taxes	$	10	$	3

Non-cash investing and financing activities	Non-cash investing and financing activities					Non-cash investing and financing activities

Property and equipment transferred to inventory						Property and equipment transferred to inventory	$	249	$	—
Inventory transferred to property and equipment (1)	Inventory transferred to property and equipment (1)	$	—	$	3,827	Inventory transferred to property and equipment (1)	$	—	$	2,830
Change in accounts payable and accrued liabilities related to purchases of property and equipment	Change in accounts payable and accrued liabilities related to purchases of property and equipment	$	(699)	$	723	Change in accounts payable and accrued liabilities related to purchases of property and equipment	$	(868)	$	1,238

(1) The non-cash transfer of inventory to property and equipment principally relates to Beacons that were transferred to the Company’s BioFoundry operations in the first and second quarter of 2021. As a result of the growth of the Company’s BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in the Company’s BioFoundry operations will be categorized as “Purchase of property and equipment.”

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

~~(14)~~(15)Commitments and Contingencies

Legal Proceedings

From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred.

AbCellera Biologics Litigation

In July 2020, AbCellera Biologics Inc. (“AbCellera”) filed a complaint in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936 and 10,704,018 (“AbCellera I”).

In August 2020, AbCellera filed a second complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,718,768, 10,738,270, 10,746,737, and 10,753,933 (“AbCellera II”). In September 2020, AbCellera filed amended complaints in each of AbCellera I and AbCellera II adding The University of British Columbia (“UBC”) as a named plaintiff. Also in September 2020, AbCellera and UBC filed a third complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,775,376, 10,775,377, and 10,775,378 (“AbCellera III”). AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the AbCellera I, AbCellera II and AbCellera III lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents and for declaratory judgment of unenforceability of the asserted

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

patents due to inequitable conduct. The Company filed a motion to transfer the AbCellera I, AbCellera II and AbCellera III lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (the “consolidated lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378.

On July 1, 2021, the court granted the Company’s motion to amend its answer and counterclaims to add federal and state unfair competition counterclaims against AbCellera Biologics; on July 22, 2021, the Company filed its amended answer and counterclaims. Also on July 1, 2021 the court issued a Case Management Order that, among other things, requires AbCellera and UBC to reduce the number of asserted patents to no more than 2,two, and the total asserted patent claims to no more than 4four per patent prior to the trial.

Also in July 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent No. 10,421,936, then filed a motion in the district court to stay the consolidated lawsuit pending the outcome of the IPR proceedings. In August 2021, the Company filed a third petition for IPR with the USPTO, challenging the validity of all asserted claims of U.S. Patent No. 10,739,270. Also in August 2021, the court granted the Company’s motion to stay the consolidated AbCellera I, AbCellera II, and AbCellera III lawsuits pending the outcome of the IPR proceedings.

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

In January 2022, the Patent Trial and Appeal Board (“PTAB”) of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. In May 2022, UBC filed a Patent Owner’s Response (“POR”) in the IPR of U.S. Patent No. ~~10,087,408.~~10,087,408, and in September 2022, the Company filed a Reply to the POR. Also in May 2022, AbCellera and UBC filed a motion in the United States District Court for the Northern District of California to lift the stay of the consolidated AbCellera I, AbCellera II, and AbCellera III lawsuits, citing lack of institution of the IPRs of U.S. Patent Nos. 10,421,936 and 10,739,270. ~~The Company has opposed~~In August 2022, the ~~motion,~~court denied AbCellera’s and ~~a hearing on the~~UBC’s motion to lift the ~~stay is scheduled for August 2022.~~stay.

In August 2020, the Company filed a complaint in the United States District Court for the Northern District of California against AbCellera and Lineage BioSciences, Inc., an entity previously acquired by AbCellera (“AbCellera IV”). The complaint included 2two counts of unfair competition and 1one count of a declaratory judgment of non-infringement of U.S. Patent No. 10,058,839. The Company was seeking, among other things, damages and a judgment of non-infringement. In October 2020, the Company filed an amended complaint asserting the same 3three counts and AbCellera and Lineage filed a motion to dismiss the amended complaint, which was granted, without prejudice, in part. In light of the Company’s amended answer and counterclaims in the consolidated lawsuits, which were amended to include its federal and state unfair competition claims as discussed above, in July 2021 the Company filed a notice of dismissal without prejudice in the AbCellera IV lawsuit, resulting in its termination.

The Company believes that the patent assertions by AbCellera and UBC are without merit and intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of its products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Securities Class Action

In December 2021, Victor J. Ng filed a securities class action complaint (the “Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 ~~IPO~~Initial Public Offering (“IPO”) offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and 3three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.

Derivative Action

In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

former senior executives owe the Company contribution for violations of sections 10(b) and 21D of the Securities Exchange Act of 1934.

The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity.

No provision has been made for litigation because the Company believes that it is not probable that a liability ~~had~~has been incurred as of ~~June~~September 30, 2022.

Product Warranty

The Company provides a 13-month assurance-type warranty, generally beginning on the shipment date, on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):


		Three months ended June 30,				Six months ended June 30,					Three months ended September 30,				Nine months ended September 30,
		2022		2021		2022		2021			2022		2021		2022		2021
Balance, beginning of period	Balance, beginning of period	$	914	$	1,268	$	1,085	$	1,271	Balance, beginning of period	$	752	$	1,190	$	1,085	$	1,271
Adjustments to existing warranties	Adjustments to existing warranties	(185)		(148)		(430)		(366)		Adjustments to existing warranties	23		(46)		(407)		(412)
Provision for new warranties	Provision for new warranties	179		242		342		617		Provision for new warranties	226		354		568		971
Settlement of pre-existing warranties	Settlement of pre-existing warranties	(156)		(172)		(245)		(332)		Settlement of pre-existing warranties	(235)		(209)		(480)		(541)
Balance, end of period	Balance, end of period	$	752	$	1,190	$	752	$	1,190	Balance, end of period	$	766	$	1,289	$	766	$	1,289

~~(15)~~(16)Net Loss Attributable to Common Stockholders Per Share

Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option ~~awards.~~awards and unvested restricted stock units. Awards granted with performance conditions are

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met.

The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):


		Three months ended June 30,				Six months ended June 30,					Three months ended September 30,				Nine months ended September 30,
		2022		2021		2022		2021			2022		2021		2022		2021

Numerator	Numerator									Numerator
Net loss attributable to common stockholders, basic and diluted	Net loss attributable to common stockholders, basic and diluted	$	(25,747)	$	(18,154)	$	(47,173)	$	(33,589)	Net loss attributable to common stockholders, basic and diluted	$	(21,566)	$	(20,403)	$	(68,739)	$	(53,992)
Denominator	Denominator									Denominator
Weighted-average shares used to compute net income per share, basic and diluted	Weighted-average shares used to compute net income per share, basic and diluted	67,985,664		66,790,755		67,842,372		66,029,307		Weighted-average shares used to compute net income per share, basic and diluted	68,384,115		67,213,282		68,024,937		66,428,303
Net loss per share	Net loss per share									Net loss per share
Net loss per share attributable to common stockholders, basic and diluted	Net loss per share attributable to common stockholders, basic and diluted	$	(0.38)	$	(0.27)	$	(0.70)	$	(0.51)	Net loss per share attributable to common stockholders, basic and diluted	$	(0.32)	$	(0.30)	$	(1.01)	$	(0.81)

~~Berkeley Lights, Inc.~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following ~~weighted-average~~shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect:


		Three and six months ended June 30,			September 30,
		2022	2021		2022	2021

Options to purchase common stock	Options to purchase common stock	7,750,612	7,619,929	Options to purchase common stock	8,105,378	7,080,020
Restricted stock units	Restricted stock units	4,241,025	470,985	Restricted stock units	4,723,138	520,494
Total	Total	11,991,637	8,090,914	Total	12,828,516	7,600,514

~~(16)~~(17)Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has 1one operating segment. The Company’s principal operations and decision-making functions are located in the United States.

Berkeley Lights, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):

Three months ended June 30, Six months ended June 30,
2022 2021 2022 2021
North America $ 9,891 $ 8,874 $ 23,585 $ 16,236
Asia Pacific (1)
7,201 9,268 12,236 17,699
Europe 2,058 1,108 3,535 3,943
$ 19,150 $ 19,250 $ 39,356 $ 37,878


	Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021

North America	$	9,315	$	11,134	$	32,900	$	27,370
Asia Pacific (1)	8,135		9,797		20,371		27,496
Europe	3,948		3,393		7,483		7,336
	$	21,398	$	24,324	$	60,754	$	62,202

(1) Asia Pacific includes Australia.

As of ~~June~~September 30, 2022 and December 31, 2021, substantially all of the Company’s long-lived assets were located in the United States.

~~(17)Subsequent Events~~

On July 21, 2022, to improve efficiency and manage operating expenses the Company terminated the employment of approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $1.1 million related to this activity, substantially all of which the Company expects to incur in the third quarter of 2022.

2224

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of forward-looking statements include, among others: our strategy to transform from a technology platform company to a diverse life sciences tools and services company; our expectations regarding the timing and strategies we plan to employ to achieve our goal of generating positive operating cash flow by early 2025; our expectations regarding anticipated returns on investment through increased focus and rigor on development initiatives; our strategy, plans and timing for acquisitions, growth, product development and expansion, including our strategy to deliver consistent commercial execution through a new sales structure and enhanced product portfolio and pricing strategy; and other expectations, outlooks and forecasts on our future business, operational and financial performance.

Forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2021 included in the Annual Report on Form 10-K and filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2022 (the “Annual Report”). Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in Item 1A. “Risk Factors” of our Annual Report, Part II, Item 1A and elsewhere in this Quarterly Report on Form 10-Q, and our other reports filed with the SEC.

Overview

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. This is a new way to capture and interpret the qualitative language of biology and translate it into single-cell specific digital information, referred to as Digital Cell Biology. We currently focus on enabling the large and rapidly growing markets of antibody therapeutics, cell therapy, gene therapy, agricultural biology and synthetic biology with our platform.

The Berkeley Lights Platform can be used to characterize the performance of cells relevant to the desired cell-based product early in the discovery process and then connect this phenotypic data to the genetic code for each cell. In contrast, current genomic technologies find sequences first and fail to deliver the functional information early in the process. Performing functional validation early means letting poorly performing cells fail early while rapidly advancing the best candidates forward, before incurring significant research and development expense. Our platform repeats this process of fail and advance many times throughout the process, delivering the best cells for what we believe will deliver the best product.

Our platform is a fully integrated, end-to-end solution, comprised of advanced automation systems, proprietary consumables, including our OptoSelect chips and reagent kits, and advanced application and workflow software. Customers load onto our system their live cell samples, as well as media and reagents, then the cells are imported onto our OptoSelect chips where integrated workflows are performed to assess specific cell functions and attributes. Our platform captures and delivers rich single-cell data to find the best cells. Our platform leverages our proprietary OptoElectro Positioning (“OEP”) technology, which enables deterministic positioning of living single cells and other micro-objects using light. OEP is a core technology of our platform and allows for a high level of control over live single cells or other micro-objects throughout the functional characterization process.

Our commercial workflows, each of which are distinct offerings, are made up of four modules we call Import, Culture, Assay and Export. These modules can be adapted, interchanged and deployed with a variety of single-cell assays to address specific applications and a variety of cell types. We believe this versatility facilitates rapid development of new workflow offerings and virtually unlimited workflow commercialization opportunities. We have developed and will continue to develop and commercialize proprietary workflows across large markets by leveraging existing workflows and assays. Over time, our goal is to enable customers to standardize many of their processes on our platform utilizing our workflows. We believe we are the only company commercializing a platform that can do this in a scalable way.

We commercially launched our platform in December of 2016, which included the Beacon system and the alpha version of our Opto Cell Line Development 1.0 workflow, targeted to the antibody therapeutics market. From the initial launch of our platform through ~~June~~September 30, 2022, we have commercially launched ten workflows. ~~In June of 2019, we launched our desktop Lightning system targeted for assay development and lower throughput workflows, and in early 2020 we launched our Culture Station instrument.~~

We focus a substantial portion of our resources on platform, workflow and assay development, as well as on business development and sales and marketing. Our research and development efforts are primarily focused on developing new workflows and assay capabilities, as well as new advanced systems and OptoSelect chips and reagent kits, to meet both our customers’ needs and to address new markets.

During 2022, we validated the unique capability on our platform to select and retrieve high-value stable producer cell lines that ~~will~~can improve the cost and therapeutically relevant yields for manufacturing Adeno-associated virus (“AAV”)-based gene therapies, which we believe represents a significant return on investment opportunity in the near term. As such, we intend to dedicate a significant number of our resources towards development of this workflow in the ~~second half~~remainder of 2022 and in 2023.

We generally outsource all of our production manufacturing. Design work, prototyping and pilot manufacturing are performed in-house before outsourcing to third party contract manufacturers. Our outsourced production strategy is intended to drive cost leverage and scale, and avoid the high capital outlays and fixed costs related to constructing and operating a manufacturing facility. The contract manufacturers of our systems are located in the United States. Contract manufacturers for reagent kits and OptoSelect chip components are located in the United States, Asia and Europe. Certain of our suppliers of components and materials are single source suppliers. We perform final manufacture and assembly steps of our OptoSelect chips in-house.

Our customer base includes several of the largest biopharmaceutical companies in the world, as well as biotechnology companies, leading contract research organizations, synthetic biology companies and academic institutions. While we have seen significant growth in our customer and installed base, we believe we are still in the very early stages of platform adoption, with the majority our historical revenue derived from early adopters of our technology for research and development purposes.

We have financed our operations primarily from the issuance and sale of equity securities, borrowings under our long-term debt agreement, and to a lesser extent from cash generated by product and service sales. On July 21, 2020, we closed our initial public offering (the “IPO”), in which we sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $22.00 per share. We received aggregate net proceeds of $187.9 million after deducting, offering costs, underwriting discounts and commissions of $17.0 million.

Since our inception in 2011, we have incurred net losses in each year. Our net losses were ~~$25.7~~$21.6 million and ~~$18.2~~$20.4 million for the three months ended ~~June~~September 30, 2022 and 2021, respectively and ~~$47.2~~$68.7 million and ~~$33.6~~$54.0 million for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively. As of ~~June~~September 30, 2022, we had an accumulated deficit of ~~$310.8~~$332.3 million and cash, cash equivalents and marketable securities totaling ~~$152.4~~$134.7 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future.

Certain of our financial results and other key operational developments ~~for the three and six months ended June 30, 2022~~ include the following:

•Total revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2022 was ~~$19.2~~$21.4 million and ~~$39.4~~$60.8 million, respectively, compared to ~~$19.3~~$24.3 million and ~~$37.9~~$62.2 million for the same periods in 2021, respectively.

•Gross profit in absolute dollarsslightly ~~increased~~decreased during the three months ended ~~June~~September 30, 2022 compared to the same period in 2021. Gross margin increased to ~~67% from 66%~~70% during the three months ended ~~June~~

September 30, 2022 compared to 63% in the same period in 2021. Gross profit increased in absolute dollars during the ~~six~~nine months ended ~~June~~September 30, 2022 compared to the same period in 2021. Gross margin for the ~~six~~nine months ended ~~June~~September 30, 2022 increased to ~~68%~~69% compared to ~~66%~~65% for the ~~six~~nine months ended ~~June~~September 30, 2021.

Strategy

In August 2022, we updated our company-wide strategy around five key pillars:

1. Generate positive operating cash flow by early 2025.

2. Prioritize research and development’s return on investment through increased focus and rigor on development initiatives.

3. Deliver consistent commercial execution through a new sales structure and enhanced product portfolio and pricing strategy.

4. Build a world-class life sciences leadership team with a proven track record in profitably scaling life sciences tools companies.

5. Evaluate merger and acquisition opportunities that will help us accelerate profitable growth and leverage our current cost structure.

By focusing on these five pillars, we believe we can transform Berkeley Lights from a technology platform company to a diverse life sciences tools and services company.

Recent Trends

~~There~~

In the second half of 2022, certain of our strategic partnership and services engagements have ended. Coupled with our focus on the AAV opportunity discussed above, we expect revenue from strategic partnership and services agreements to decline in the near term. For additional information, see “Risk Factors—Our revenue under our customer sales engagements, program and service agreements and strategic partnerships and services for any particular period can be difficult to forecast.” in Part II, Item 1A in this Quarterly Report on Form 10-Q.

In addition, there are multiple broad based factors impacting our business:

1.~~First, the~~The COVID-19 pandemic has had, and continues to have, a significant impact around the world, prompting governments and businesses to take unprecedented measures, including temporary closures of businesses, quarantines and shelter in place orders.

2.Global and domestic supply chains and the timely availability of raw materials and products have been and may continue to be materially disrupted by quarantines, factory slowdowns or shutdowns, border closings and travel restrictions resulting from the COVID-19 pandemic.

3.~~The COVID-19 pandemic, in addition to other macroeconomic~~Macroeconomic factors including the war between Ukraine and Russia as well as political instability in the United States, the United Kingdom and elsewhere, has resulted in unfavorable global economic conditions including increased inflation and interest ~~rates.~~rates and may lead to a recession.

Our business has been impacted and will continue to be impacted by the above factors, by among other things, the following:

2527

In the second half of 2022, certain of our strategic partnership and services engagements are ending. Coupled with our focus on the AAV opportunity discussed above, we expect revenue from strategic partnership and services agreements to decline in the near term.

In addition, pandemic related lockdowns in China throughout the first quarter of 2022 adversely impacted the operation of our office in Shanghai, in which the majority of our employees in our Asia Pacific region reside. While the city-wide lockdowns were lifted in the second quarter of 2022, localized lockdowns still remain.

To date, our production, shipping and customer service functions have remained operational to maintain a continuous supply of products both to our customers and for our internal research and development activities. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future activities. We continue to closely monitor global supply issues around materials, parts and components, including plastics and integrated circuit chips, and we have not experienced any material supply issue to date.

The ultimate impact of COVID-19 and unfavorable economic conditions on our operations and financial performance in future periods remains uncertain and will depend on many factors outside our control, including the timing, extent, trajectory, and duration of the pandemic as well as the magnitude of any potential recession and related government actions to prevent and manage these issues, all of which are uncertain and cannot be predicted. While the overall impact of ~~COVID-19 and unfavorable economic conditions~~these matters is impossible to measure, they have resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and, ultimately our business and operations. Refer to Part I, Item 1A of our Annual Report and Part II, Item 1A in this Quarterly Report on Form 10-Q under the heading “Risk Factors” for more information.

Results of operations

Comparison of the three and nine months ended September 30, 2022 and 2021

Revenue


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Platform	$	11,760	$	14,128	$	(2,368)	(17)	%	$	25,590	$	36,633	$	(11,043)	(30)	%
Recurring	7,024		4,733		2,291		48	%	18,396		13,073		5,323		41	%
Partnerships	2,614		5,463		(2,849)		(52)	%	16,768		12,496		4,272		34	%
Total revenue	$	21,398	$	24,324	$	(2,926)	(12)	%	$	60,754	$	62,202	$	(1,448)	(2)	%

See Note 5 to our condensed consolidated financial statements for additional information regarding how our product and service revenue is generated through our platform, recurring and partnerships revenue streams.

Platform revenue decreased by $2.4 million, or 17%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. During the three months ended September 30, 2022 we placed eight platforms, compared to thirteen platforms placed during the three months ended September 30, 2021.

Recurring revenue increased by $2.3 million, or 48%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. The increase was primarily driven by an increase of $1.2 million in consumables revenue, a $1.0 million increase in extended warranty arrangements and an increase of $0.1 million in subscription arrangements.

Partnerships revenue decreased by $2.8 million, or 52%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. This decrease is primarily due to our active collaboration agreement with Ginkgo Bioworks, Inc. (“Ginkgo”) winding down prior to the anticipated contract

end date during the third quarter of 2022. We determined we would be unable to reach an agreement with Ginkgo on potential changes to such agreement partly due to the limited margin benefit of the existing agreement to us.

Platform revenue decreased by $11.0 million, or 30%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. During the nine months ended September 30, 2022 we placed seventeen platforms, compared to thirty platforms placed during the nine months ended September 30, 2021.

Recurring revenue increased by $5.3 million, or 41%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. The increase was primarily driven by an increase of $2.0 million in consumables revenue, a $3.0 million increase in extended warranty arrangements and an increase of $0.3 million in subscription arrangements.

Partnerships revenue increased by $4.3 million, or 34%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. The increase was primarily due to higher revenue from our strategic partnerships and services agreements signed in 2021, partially offset by the winding down of the active collaboration agreement with Ginkgo discussed above.

Cost of sales, gross profit and gross margin


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Cost of sales	$	6,373	$	8,911	$	(2,538)	(28	%)	$	18,976	$	21,610	$	(2,634)	(12	%)
Gross profit	$	15,025	$	15,413	$	(388)	(3	%)	$	41,778	$	40,592	$	1,186	3	%
Gross margin	70 %		63 %						69 %		65 %

Cost of sales for the three and nine months ended September 30, 2022 decreased by $2.5 million and $2.6 million, respectively, compared to the corresponding periods in 2021 and was primarily due to the decline in revenue and the changes in gross margin disclosed below.

Gross margin for both the three and nine months ended September 30, 2022 increased compared to the corresponding periods in 2021 due to the winding down of the active collaboration agreement with Ginkgo during the third quarter of 2022. We determined that we would be unable to reach an agreement with Ginkgo partly due to such agreement’s limited margin benefit to us and our stated preference for prioritizing higher value projects that support our margin and profitability goals.

Operating Expenses

Organizational and presentational changes

During the third quarter of 2022, we made certain changes to our operating structure to align with our new business strategy. These changes included reorganizing our go-to-market efforts, the termination of approximately 12% of our workforce (see Note 12 to our condensed consolidated financial statements for additional information), and additional organizational changes.

As part of these changes, our “service center,” a team of scientists and engineers who perform services for both our internal and external projects, is now part of our platform sales and support organization. The service center historically reported to our former Chief Product Officer.

As a result of these changes, we have updated our classification of operating expenses as follows:

1. Expenses related to the termination of employees during the third quarter discussed above are classified in “Restructuring” within Operating Expenses.

2. We now disclose “Selling, general and administrative” expenses which includes expenses historically reported in “Sales and marketing” as well as “General and administrative” expenses. We have reclassified the prior period to conform to the current period presentation for this change.

3. Expenses associated with our service center are no longer classified as “Research and development” expenses, and are instead classified as “Selling, general and administrative” expenses on our condensed consolidated statements of operations as of the third quarter of 2022.


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Research and development	$	8,978	$	16,195	$	(7,217)	(45	%)	$	44,729	$	42,757	$	1,972	5 %
Selling, general and administrative	26,525		19,198		7,327		38	%	64,347		50,813		13,534		27 %
Restructuring	1,058		—		$	1,058	100	%	$	1,058	$	—	$	1,058	100 %
Total operating expenses	$	36,561	$	35,393	$	1,168	3	%	$	110,134	$	93,570	$	16,564	18 %

Operating expenses increased by $1.2 million, or 3%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. The increase is primarily due to restructuring expenses incurred in connection with the termination of approximately 12% of our workforce during the third quarter of 2022, partially offset by cost reductions in research and development, which are partially attributable to the restructuring activities in the quarter.

Operating expenses increased by $16.6 million, or 18%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. The increase was primarily due higher personnel costs, including stock-based compensation, due to higher average headcount, higher depreciation expense and increased costs to support our operations.

Research and development expense decreased by $7.2 million, or 45%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. This decrease reflects the impact of the $4.7 million reclassification of the service center expenses discussed above.In addition, research and development expense decreased during the period due to the impact of the 12% workforce reduction discussed above and lowered spend due to our strategy to prioritize research and development return on investment through increased focus and rigor on development initiatives.

Research and development expense increased by $2.0 million, or 5%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. The increase was primarily due to increased costs during the first half of the year, partially offset by the cost reductions that occurred in the third quarter of 2022 described above. Research and development expense for the nine months ended September 30, 2022 reflect the impact of the $4.7 million reclassification of the service center expenses discussed above.

Selling, general and administrative expense increased by $7.3 million, or 38%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021. This increase reflects the impact of the $4.7 million reclassification of the service center expenses discussed above. In addition, selling, general and administrative costs increased due to higher personnel expenses, increased legal fees and increased costs to support our operations.

Selling, general and administrative expense increased by $13.5 million or 27%, for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021. This increase reflects the impact of the $4.7 million reclassification of the service center expenses discussed above. In addition, selling, general and administrative costs increased due to an increase in personnel expenses and other costs to support our operations.

Interest expense


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Interest expense	$	229	$	232	$	(3)	(1	%)	$	680	$	942	$	(262)	(28	%)

Interest expense was flat for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. Interest expense decreased by $0.3 million during the nine months ended September 30, 2022 compared to the corresponding period in 2021, as a result of refinancing our loan from East West Bank on June 30, 2021, which now carries a lower interest rate.

Interest income


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Interest income	$	465	$	33	$	432	1309	%	$	552	$	142	$	410	289	%

Interest income increased by $0.4 million during each of the three and nine months ended September 30, 2022 as compared to the corresponding periods in 2021. These increases are primarily the result of higher yields received on our cash management program.

Other expense, net


	Three months ended September 30,				Three month change				Nine months ended September 30,				Nine month change
(in thousands, except percentages)	2022		2021		Amount		%		2022		2021		Amount		%
Other expense, net	$	(244)	$	(170)	$	(74)	(44	%)	$	(209)	$	(117)	$	(92)	(79	%)

Other expense, net for the three and nine months ended September 30, 2022 and 2021 was mainly comprised of foreign exchange gains and losses and other miscellaneous income and expense items.

Components of results of operations

Revenue

Our revenue consists of ~~both product revenue~~platform, recurring and ~~service revenue, which is generated through the following revenue streams: (i) direct platform sales, (ii) recurring revenue,~~ ~~and (iii) strategic~~ partnerships ~~and servicesagreements. Sales~~revenue. Platform revenue consists of the sale of advanced automation systems ~~recurring~~(including the Beacon, Lightning and Culture Station), associated software, fixed-term sales-type lease arrangements with qualified customers, as well as application support, installation and training. Recurring revenue ~~from consumables,~~includes quarterly workflow ~~subscription agreements,~~subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess), and ~~workflow licenses are defined~~fixed fee extended warranty and service programs. Partnerships revenue consists of strategic partnerships, as ~~product revenue, and revenue from strategic partnership and services agreements and extended or enhanced warranty contracts, feasibility studies and platform support are defined~~well as ~~service revenue in our consolidated results of operations. We launched our Tech Access subscription model in June 2021.~~

~~The following tables provide an overview of our revenue streams and how we report revenue in our consolidated statements of operations (in thousands):~~

~~Income Statement Classification~~

~~Product or Service sold~~

~~Revenue Stream~~

~~Product revenue~~

~~Sale of advanced automation system (Beacon and Lightning system, Culture Station)~~

~~Direct platform sales~~

~~Software~~

~~Direct platform sales~~

~~Fixed term sales-type lease arrangements with qualified customers~~

~~Direct platform sales~~

~~Annual renewable workflow licenses, quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess)~~

~~Recurring revenue~~

~~Consumables and reagent kits (e.g. OptoSelect chips)~~

~~Recurring revenue~~

~~Service revenue~~

~~Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types~~

~~Strategic partnerships and services~~

~~Application support, installation and training~~

~~Direct platform sales~~

~~Fixed fee extended warranty and service programs~~

~~Recurring revenue~~

~~We renamed our~~ joint development and ~~partnership offering to strategic partnerships and~~collaboration agreements where we provide services ~~in the fourth quarter of 2021.~~

Three months ended June 30, 2022 Six months ended June 30, 2022
(in thousands) Product Service Total Product Service Total
Direct platform sales $ 6,226 $ 200 $ 6,426 $ 12,973 $ 857 $ 13,830
Recurring revenue 3,242 2,687 5,929 6,269 5,103 11,372
Strategic partnerships and services — 6,795 6,795 — 14,154 14,154
Total revenue $ 9,468 $ 9,682 $ 19,150 $ 19,242 $ 20,114 $ 39,356

Three months ended June 30, 2021 Six months ended June 30, 2021
(in thousands) Product Service Total Product Service Total
Direct platform sales $ 10,717 $ 672 $ 11,389 $ 21,303 $ 1,202 $ 22,505
Recurring revenue 2,304 1,642 3,946 5,251 3,089 8,340
Strategic partnerships and services — 3,915 3,915 — 7,033 7,033
Total revenue $ 13,021 $ 6,229 $ 19,250 $ 26,554 $ 11,324 $ 37,878

~~The following tables provide information by revenue stream~~ for the ~~periods presented:~~

development of new workflows, cells or organism types. See Note 5 to our condensed consolidated financial statements for
additional information regarding how our product and service revenue is generated through our platform, recurring and partnerships revenue streams.

Three months ended June 30,
(in thousands, except percentages) 2022 2021 Change
Direct platform sales $ 6,426 $ 11,389 $ (4,963) (44) %
Recurring revenue 5,929 3,946 1,983 50 %
Strategic partnerships and services 6,795 3,915 2,880 74 %
Total revenue $ 19,150 $ 19,250 $ (100) (1) %

Six months ended June 30,
(in thousands, except percentages) 2022 2021 Change
Direct platform sales $ 13,830 $ 22,505 $ (8,675) (39) %
Recurring revenue 11,372 8,340 3,032 36 %
Strategic partnerships and services 14,154 7,033 7,121 101 %
Total revenue $ 39,356 $ 37,878 $ 1,478 4 %

~~Costs~~Cost of sales, gross profit and gross margin

~~Product cost~~Cost of sales. Cost of sales ~~associated with our products primarily consists of~~includes manufacturing related costs incurred in the production process, including personnel and related costs, costs of component materials, labor and overhead, packaging and delivery costs and allocated costs, including facilities and information technology. ~~These costs also include the costs associated with the standard assurance-type product warranty provided on our platforms, which are recorded at the time of sale.~~

~~Service~~Also included in cost of sales are the personnel and related costs~~. Cost of sales~~ associated with our services, ~~primarily consists of personnel and related costs,~~ expenses related to the development of customized platforms and workflows, feasibility studies on our platforms and service and warranty costs to support our customers. We ~~maintain continuous efforts to increase reliability and uptime~~also include the costs associated with the standard assurance-type product warranty provided on our platforms, which are recorded at the time of ~~our advanced automation systems.~~sale.

Gross profit and gross margin. Gross profit is calculated as revenue less cost of sales. Gross margin is gross profit expressed as a percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including: market conditions that may impact our pricing; sales mix among platform access options, including the regional mix of sales; sales mix changes among consumables, advanced automation systems and services; product mix changes between established products and new products; excess and obsolete inventories; our cost structure for manufacturing operations relative to volume; and product warranty obligations. We expect cost of sales to increase in absolute dollars in future periods as our revenue ~~grows, and as we plan to hire additional employees to support our manufacturing, operations, service and support organizations.~~grows.

Gross profit was $12.9 million and $26.8 million for the three and six months ended June 30, 2022, respectively. Gross profit was $12.7 million and $25.2 million for the three and six months ended June 30, 2021, respectively.

Operating expenses

Research and development. Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses and allocated facilities and IT costs for employees and contractors engaged in research and product development. We expense all research and development costs in the period in which they are incurred.

We plan to continue to invest in our research and development efforts, including hiring additional employees, to enhance existing products and develop new products. As a result, we expect that our research and development expenses will continue to increase in absolute dollars in future periods. We expect these expenses to vary from period to period as a percentage of revenue.

~~General~~Selling, general and administrative. Our selling, general and administrative expenses primarily consist of costs related to the selling and marketing of our products and services and costs associated with our executive, finance, accounting, legal, human resources and administrative functions. These costs include salaries, benefits, sales commissions and stock-based compensation ~~costs~~ for ~~employees in~~ our ~~executive, accounting and finance, legal and human resource functions,~~employees, as well as advertising and marketing costs and professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company. We expect these expenses to vary from period to period as a percentage of revenue.

~~Sales and marketing.~~Restructuring. Our ~~sales and marketing expenses consist primarily~~restructuring expense consists of ~~salaries,~~one-time cash severance benefits ~~sales commissions and stock-based compensation costs~~associated with the termination of certain employees during the third quarter of 2022 (see Note 12 to our condensed consolidated financial statements for employees within our commercial sales functions, as well as marketing, travel expenses and allocated facilities and IT costs. We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams, increase our presence globally and increase marketing activities to drive awareness and adoption of our platform. While these expenses may vary from period to period as a percentage of revenue, we expect these expenses to increase as a percent of sales in the short-term as we continue to grow our commercial organization to support anticipated growth in the business.additional information).

Other income (expense)

Interest expense. Interest expense consists primarily of interest related to borrowings under our debt obligations.

Interest income. Interest income primarily consists of interest earned on our cash, ~~and~~ cash equivalents ~~which are invested in cash deposits~~ and ~~in money market funds.~~short-term available-for-sale debt securities.

Other income (expense), net. Other income (expense), net consists primarily of foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and asset and liability balances denominated in currencies other than the U.S. dollar, primarily related to our operations in the United Kingdom and China. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.

Provision for income taxes

Our provision for income taxes consists primarily of foreign taxes and state taxes in the United States. The Company maintains a full valuation allowance on its deferred tax assets and intends to do so until there is sufficient evidence to support the reversal of all or some portion of these allowances. As we expand the scale and scope of our international business activities, any changes in taxation of such activities may increase our overall provision for income taxes in the future.

~~Results of operations~~

~~The following tables set forth our results of operations for the periods presented:~~

Three months ended June 30, Six months ended June 30,
(in thousands) 2022 2021 2022 2021
Revenue:
Product revenue $ 9,468 $ 13,021 $ 19,242 $ 26,554
Service revenue 9,682 6,229 20,114 11,324
Total revenue 19,150 19,250 39,356 37,878
Cost of sales:
Product cost of sales 2,614 3,332 5,309 7,035
Service cost of sales 3,610 3,190 7,294 5,664
Total cost of sales (1)
6,224 6,522 12,603 12,699
Gross profit 12,926 12,728 26,753 25,179
Operating expenses:
Research and development (1)
18,178 13,535 35,751 26,562
General and administrative (1)
13,024 11,725 24,740 20,692
Sales and marketing (1)
7,271 5,317 13,082 10,923
Total operating expenses 38,473 30,577 73,573 58,177
Loss from operations (25,547) (17,849) (46,820) (32,998)
Other income (expense):
Interest expense (227) (356) (451) (710)
Interest income 53 43 87 109
Other income (expense), net (22) 34 35 53
Loss before income taxes (25,743) (18,128) (47,149) (33,546)
Provision for income taxes 4 26 24 43
Net loss $ (25,747) $ (18,154) $ (47,173) $ (33,589)

~~(1)Amounts include stock-based compensation as follows:~~

Three months ended June 30, Six months ended June 30,
(in thousands) 2022 2021 2022 2021
Cost of sales $ 68 $ 63 $ 119 $ 105
Research and development 2,292 1,599 3,873 2,660
General and administrative 2,318 2,497 4,529 3,869
Sales and marketing 1,887 1,470 3,437 3,489
Total stock-based compensation expense $ 6,565 $ 5,629 $ 11,958 $ 10,123

~~Comparison of the three and six months ended June 30, 2022 and 2021~~

~~Revenue~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Product revenue $ 9,468 $ 13,021 $ (3,553) (27 %) $ 19,242 $ 26,554 $ (7,312) (28 %)
Service revenue 9,682 6,229 3,453 55 % 20,114 11,324 $ 8,790 78 %
Total revenue $ 19,150 $ 19,250 $ (100) (1) % $ 39,356 $ 37,878 $ 1,478 4 %

Product revenue decreased by $3.6 million, or 27%, for the three months ended June 30, 2022, compared to the three months ended June 30, 2021. The decrease was primarily due to lower platform and system sales of $4.5 million, including sales-type lease arrangements, partially offset by an increase of $0.9 million in consumable sales driven by a higher installed platform base and an increase of $0.1 million in subscription arrangements and related revenue. During the three months ended June 30, 2022 we placed five platforms, compared to seven platforms placed during the three months ended June 30, 2021.

Service revenue increased by $3.5 million, or 55%, for the three months ended June 30, 2022, compared to the three months ended June 30, 2021. The increase was primarily driven by higher revenue associated with strategic partnerships and services agreements of $2.9 million, due to work performed on agreements signed in the second half of 2021, as well as an increase in service warranty and application support agreements of $0.6 million, which resulted from a higher installed platform base.

Product revenue decreased by $7.3 million, or 28%, for the six months ended June 30, 2022, compared to the six months ended June 30, 2021. The decrease was primarily due to lower platform and system sales of $8.3 million, including sales-type lease arrangements, partially offset by an increase of $0.8 million in consumable sales due to a higher installed platform base and an increase of $0.2 million in subscription arrangements and related revenue. During the six months ended June 30, 2022 we placed nine platforms, compared to seventeen platforms placed during the six months ended June 30, 2021.

Service revenue increased by $8.8 million, or 78%, for the six months ended June 30, 2022, compared to the six months ended June 30, 2021. The increase was primarily driven by higher revenue associated with strategic partnerships and services agreements of $7.1 million as well as an increase in service warranty and application support agreements of $1.7 million, which resulted from a higher installed platform base.

~~Cost of sales, gross profit and gross margin~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Product cost of sales $ 2,614 $ 3,332 $ (718) (22 %) $ 5,309 $ 7,035 $ (1,726) (25 %)
Service cost of sales 3,610 3,190 420 13 % 7,294 5,664 1,630 29 %
Total cost of sales $ 6,224 $ 6,522 $ (298) (5 %) $ 12,603 $ 12,699 $ (96) (1 %)
Gross profit $12,926 $12,728 $ 198 2 % $ 26,753 $ 25,179 $ 1,574 6 %
Gross margin 67 % 66 % 68 % 66 %

Product cost of sales for the three months ended June 30, 2022 decreased by $0.7 million, or 22%, compared to the three months ended June 30, 2021 and was due to the decline in product revenue and the favorable impact of settlements and adjustments to our warranty liabilities.

~~Service cost of sales~~ ~~increased~~ ~~by $0.4 million, or~~ ~~13%, by during the three months ended June 30, 2022, compared to the three months ended June 30, 2021 due to increased costs for our strategic partnerships and services agreements.~~

Product cost of sales for the six months ended June 30, 2022 decreased by $1.7 million, or 25%, compared to the six months ended June 30. 2022. The decrease was primarily driven by lower revenue from our platform and system sales, including sales-type lease arrangements and the favorable impact of settlements and adjustments to our warranty liabilities.

~~Service cost of sales for the six months ended June 30, 2022 increased by $1.6 million, or~~ ~~29%~~, compared to the six months ended June 30, 2021 primarily as a result of higher costs associated with our extended warranty plans and increased costs associated with our strategic partnerships and services agreements.

~~Gross profit increased by $0.2 million, or~~ 2%~~, during the three months ended June 30, 2022, compared to the three months ended June 30, 2021. Gross margin increased to~~ ~~67%~~ ~~from~~ ~~66%~~ ~~for the three months ended June 30, 2022, compared to the three months ended June 30, 2021.~~

~~Gross profit increased by $1.6 million, or~~ 6%~~, during the six months ended June 30, 2022, compared to the six months ended June 30, 2021. Gross margin increased to~~ ~~68%~~ ~~from~~ ~~66%~~ ~~for the six months ended June 30, 2022, compared to the six months ended June 30, 2021.~~

Gross profit for both the three months and six months ended June 30, 2022 were positively impacted by the fact that the strategic partnerships and services agreements we entered into in 2021 have a higher margin than our previous strategic partnership and services agreements, of which the largest was our collaboration agreement with Ginkgo Bioworks, Inc.

~~Operating Expenses~~

~~Research and development~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Research and development $ 18,178 $ 13,535 $ 4,643 34 % $ 35,751 $ 26,562 $ 9,189 35 %

Research and development expense increased by $4.6 million, or 34%, and by $9.2 million, or 35%, respectively, for the three and six months ended June 30, 2022, compared to the three and six months ended June, 30, 2021. The increases were primarily due to increased personnel-related expenses, including a $0.7 million and $1.2 million increase in stock-based compensation in each of the periods, respectively, as well as increases in other costs, including testing and qualification materials and other costs related to various projects to develop and improve systems, workflows, consumables and assays.

~~General and administrative~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
General and administrative $ 13,024 $ 11,725 $ 1,299 11 % $ 24,740 $ 20,692 $ 4,048 20 %

~~General and administrative expense increased by $1.3 million, or~~ ~~11%, and by $4.0 million, or~~ ~~20%~~, respectively, for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. The increases were primarily due to increased personnel-related expenses, including an increase (decrease) in stock-based compensation expense of ($0.2 million) and $0.7 million for the three and six months ended June 30, 2022, respectively, and increased costs to improve our information processes and other infrastructure required for a public company, partially offset by a decrease in outside legal fees related to patent litigation.

~~Sales and marketing~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Sales and marketing $ 7,271 $ 5,317 $ 1,954 37 % $ 13,082 $ 10,923 $ 2,159 20 %

Sales and marketing expense increased by $2.0 million, or 37%, and by $2.2 million, or 20%, respectively, for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. The increase was primarily due to increased personnel-related expenses, including an increase (decrease) in stock-based compensation expense of $0.4 million and ($0.1 million) for the three and six months ended June 30, 2022, respectively, and also due to an overall increase in marketing, advertising and other sales costs.

~~Interest expense~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Interest expense $ 227 $ 356 $ (129) (36 %) $ 451 $ 710 $ (259) (36 %)

Interest expense decreased by $0.1 million, or 36%, and $0.3 million, or 36%, respectively, for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021, as a result of refinancing our loan from East West Bank, which now carries a lower interest rate.

~~Interest income~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Interest income $ 53 $ 43 $ 10 23 % $ 87 $ 109 $ (22) (20 %)

Interest income was flat for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. We generate interest income through our cash and short-term deposits, and also through short-term available-for-sale marketable securities, which we invested during the latter part of the second quarter of 2022.

~~Other income (expense), net~~

Three months ended June 30, Three month change Six months ended June 30, Six month change
(in thousands, except percentages) 2022 2021 Amount % 2022 2021 Amount %
Other income (expense), net $ (22) $ 34 $ (56) (165 %) $ 35 $ 53 $ (18) (34 %)

~~Other income for the three and six months ended June 30, 2022 and 2021 was mainly comprised of foreign exchange gains and losses and other miscellaneous income and expense items.~~

Liquidity and capital resources

As of ~~June~~September 30, 2022, we had approximately ~~$152.4~~$134.7 million in cash and cash equivalents and marketable securities which were primarily held in U.S. short-term bank deposit accounts and other investment grade short-term available-for-sale debt securities. Restricted cash at December 31, 2021 of $0.3 million served as collateral for our corporate credit card program. This amount is no longer restricted as of ~~June~~September 30, 2022. We have generated negative cash flows from operations since inception through ~~June~~September 30, 2022.

We expect to incur additional operating losses in the foreseeable future as we continue to invest in the research and development of our product offerings, commercialize and launch platforms, and expand into new markets. Our future capital requirements will depend on many factors including our revenue growth rate, research and development efforts, the timing and extent of additional capital expenditures to invest in existing and new facilities as well as our manufacturing operations, the expansion of sales and marketing and the introduction of

new products. Our future capital needs may also depend upon the impacts of the COVID-19 ~~pandemic.~~pandemic and other factors affecting the macroeconomic environment. We have and may in the future enter into arrangements to acquire or invest in businesses, services and technologies, and any such acquisitions or investments could significantly increase our capital needs.

Based on our current business plan, we believe our existing cash and cash equivalents and anticipated cash flows from operations will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months.

Sources of liquidity

Since our inception, we have financed our operations primarily from the issuance and sale of our equity securities, borrowings under long-term debt agreements, and to a lesser extent, cash generated by product and service sales. In July 2020, we completed our IPO, resulting in the receipt of aggregate proceeds of $187.9 million, net of offering costs, underwriter discounts and commissions of $17.0 million.

East West Bank Loan and Security Agreement

On May 23, 2018, we entered into a Loan and Security Agreement with East West Bank (“EWB”) providing us the ability to borrow up to $20.0 million. The loan facility was fully drawn as of May 23, 2018.

On June 30, 2021, we entered into an Amended and Restated Loan and Security Agreement (the “Agreement”) with EWB. Pursuant to the Agreement, EWB provided a $20.0 million term loan (the “Term Loan”) which was used to refinance the term loan outstanding under the Loan and Security Agreement dated May 23, 2018. The Term Loan matures in 48 months and bears interest at a fixed rate of 4.17%. The Term Loan has an initial interest-only period of 24 months, which can be extended to up to 36 months based on the achievement of certain liquidity measures, and can be pre-paid without penalty at any time.

The Agreement grants EWB a security interest in and liens on all of our assets, excluding intellectual property, which is subject to a double negative pledge. In addition, certain other terms of the original agreements as previously in effect were amended by the Agreement, including certain financial covenants. The Amended and Restated Loan and Security Agreement was accounted for as a debt modification and we capitalized incremental debt issuance costs.

Furthermore, the Agreement also provided the Company with a new $10.0 million revolving credit line (the “Revolving Line”), which bears interest on the outstanding daily balance thereof of 0.70% above the Prime Rate (as defined in the Agreement). No amount was outstanding under the Revolving Line as ~~at June~~of September 30, ~~2022.~~2022.

We were in compliance with all covenants under the Agreement as of ~~June~~September 30, 2022.

Cash flows

The following table summarizes our cash flows for the periods presented:

Six months ended June 30,
(in thousands) 2022 2021
Net cash (used in) provided by:
Operating activities $ (20,588) $ (24,095)
Investing activities (16,130) (4,382)
Financing activities 1,376 10,146
Net decrease in cash and cash equivalents and restricted cash $ (35,342) $ (18,331)


	Nine months ended September 30,
(in thousands)	2022		2021
Net cash (used in) provided by:
Operating activities	$	(37,503)	$	(38,710)
Investing activities	(21,775)		(10,715)
Financing activities	1,552		13,018
Net decrease in cash and cash equivalents and restricted cash	$	(57,726)	$	(36,407)

3534

Operating activities

Net cash used in operating activities of ~~$20.6~~$37.5 million for the ~~six~~nine months ended ~~June~~September 30, 2022 was attributable to a net loss of ~~$47.2~~$68.7 million, partially offset by non-cash adjustments of ~~$18.7~~$26.9 million, mainly consisting of stock-based compensation and depreciation expense, and a net cash inflow from changes in our operating assets and liabilities of ~~$7.8~~$4.4 million, primarily due to a decrease in our accounts ~~receivable.~~receivable, partially offset by an decrease in deferred revenue.

Net cash used in operating activities of ~~$24.1~~$38.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021 was attributable to a net loss of ~~$33.6~~$54.0 million and cash outflows from changes in our net operating assets and liabilities of ~~$4.7~~$6.9 million, partially offset by ~~$14.2~~$22.2 million of non-cash charges, primarily related to stock-based compensation and depreciation ~~and amortization.~~expense. Cash outflow from our net operating assets and liabilities was primarily due to an increase in inventories ~~resulting from an increase in raw materials~~ and ~~finished goods, an increase in~~ accounts receivable, ~~due to an increase in revenue and the timing of invoicing,~~ partially offset by an increase in deferred revenue and accounts ~~payable due to the timing of advanced billings and revenue recognition as well as the timing of vendor invoicing and related payments.~~payable.

Investing activities

Net cash used in investing activities ~~was $16.1~~of $21.8 million during the ~~six~~nine months ended ~~June~~September 30, 2022 ~~compared to $4.4 million during the six months ended June 30, 2021. The increase~~ was primarily ~~driven by~~attributable to the net purchase of ~~$9.4~~$14.0 million of available-for-sale marketable securities during the ~~second~~third quarter of 2022 and ~~$6.8~~$7.7 million of purchases of property, plant and equipment.

Capital expenditures for the first ~~six~~nine months of 2022 include the expansion of our BioFoundry laboratory operations to support current and planned programs as well as leasehold improvements related to our new offices in Boston, Massachusetts.

Net cash used in investing activities was ~~$4.4~~$10.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021 and related to capital expenditures for the expansion of our BioFoundry laboratory. Capital expenditures for the ~~six~~nine months ended ~~June~~September 30, 2021 exclude a ~~$3.8~~$2.8 million non-cash transfer of Beacons that were purchased into inventory and later transferred to property and equipment. As a result of the growth of our BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in our BioFoundry operations are categorized as “Purchase of property and equipment.”

Financing activities

Net cash provided by financing activities was ~~$1.4~~$1.6 million during the ~~six~~nine months ended ~~June~~September 30, 2022, compared to ~~$10.1~~$13.0 million for the ~~six~~nine months ended ~~June~~September 30, ~~2021.~~2021. Net cash provided by financing activities during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 primarily related to proceeds received from the issuance of common stock upon exercise of stock options as well as proceeds received related to the issuance of common stock under our employee stock purchase plan.

Concentration of credit risk

Most of the Company’s customers are located in the United States and Asia Pacific. For the three months ended ~~June~~September 30, 2022, ~~three~~two customers accounted for ~~20%, 11%,~~26% and 10% of revenue. For the ~~six~~nine months ended ~~June 30.~~September 30, 2022, ~~three customers~~one customer accounted for ~~16%, 11% and 10%~~19% of revenue. For the three months ended ~~June~~September 30, 2021, four customers accounted for 16%, 15%, 10% and 10% of revenue. For the nine months ended September 30, 2021, three customers accounted for ~~27%~~21%, ~~18%, and 11% of revenue. For the six months ended June 30, 2021, three customers accounted for 14%, 11%~~15% and 10% of revenue.

As of ~~June~~September 30, 2022, ~~three~~two customers comprised ~~27%, 12%,~~30% and ~~11%~~14% of accounts receivable. As of December 31, 2021, three customers accounted for 15%, 11% and 11% of accounts receivable.

3635

Contractual obligations and commitments

There have been no material changes to our contractual obligations as of ~~June~~September 30, 2022, as compared to those disclosed in the Annual Report, ~~on Form 10-K for~~with the ~~year ended~~exception of purchase obligations. Purchase obligations decreased from $43.6 million as of December 31, ~~2021.~~2021 to $38.4 million as of September 30. 2022.

Off-balance sheet arrangements

We do not have, and did not have during the periods presented, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities, that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Critical accounting policies and estimates

We have prepared our condensed consolidated financial statements in accordance with United States generally accepted accounting principles. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled “Management’s Discussion and Analysis of Financial Condition and Operations” included in our Annual Report ~~on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022,~~ with the following exceptions.

Stock-Based Compensation

We maintain an incentive compensation plan under which stock options and restricted stock units (“RSU”) are granted to employees, non-employee consultants and ~~non-employee consultants.~~directors.

Stock-based compensation expense is calculated based on the grant date fair value of the award. We determine the fair value of RSUs based on the closing ~~value~~price of our common stock ~~price listed~~as reported by Nasdaq on ~~the Nasdaq at~~ the date of the grant.

We estimate the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) we use a Monte Carlo simulation to estimate the fair value.

For performance stock options and ~~awards~~RSUs not initially assessed as probable of achievement, we record a cumulative adjustment to compensation expense in the period we change our determination that a performance condition becomes probable of being achieved. We cease recognition of compensation expense in any periods

3736

where we determine the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Interest rate risk

Customer financing exposure. We are indirectly exposed to interest rate risk because many of our customers depend on debt financings to purchase our platforms and systems. An increase in interest rates could make it challenging for our customers to obtain the capital necessary to make such purchases on favorable terms, or at all. Such factors could reduce demand or lower the price we can charge for our platforms and systems, thereby reducing our net sales and gross profit.

Bank deposit, money market and marketable securities exposure. As of ~~June~~September 30, 2022, we had cash and cash equivalents and available-for-sale marketable debt securities, of ~~$152.4~~$134.7 million, which consisted primarily of money market funds, bank deposits and debt instruments of high quality corporate issuers and the U.S. government. The primary objective of our investments is to facilitating liquidity and capital preservation. None of our investments are held for trading purposes. These short-term investments generate interest income at rates typically between 1% and 3%4%. A hypothetical 100 basis point decrease in interest rates would have no material effect on our interest income and financial results.

Foreign currency risk

Through ~~June~~September 30, 2022, we did not generate any revenue denominated in foreign currencies. While we incur certain expenses in foreign currencies, especially related to our foreign offices, the impact of changes in exchange rates has been immaterial as of ~~June~~September 30, 2022 for these expenses. As we expand our presence in international markets, to the extent we are required to enter into agreements denominated in a currency other than the U.S. dollar, our results of operations and cash flows may increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, our principal executive officer and principal financial officer concluded that as of ~~June~~September 30, 2022 our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

We also carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of our “internal control over financial reporting” to determine whether any changes in our internal control over financial reporting occurred during the three months ended ~~June~~September 30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no such changes in our internal control over financial reporting that occurred during the three months ended ~~June~~September 30, 2022.

Limitations on the Effectiveness of Controls

Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any system of controls must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Part II. OTHER INFORMATION.

Item 1. Legal Proceedings.

See Note ~~14, “Commitments and Contingencies” under the heading “Legal Proceedings” in the Notes~~15 to ~~the Unaudited Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q~~our condensed consolidated financial statements for legal proceedings and related matters.

Item 1A. Risk Factors.

Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in our Annual Report and below in this Quarterly Report:

Our revenue under our customer sales engagements, program and service agreements and strategic partnerships and services for any particular period can be difficult to forecast.

Because of the complexities and long sales cycles inherent in our business, including, in particular, certain customer feasibility study agreements and collaboration and development agreements, it is difficult to predict the timing of a customer’s purchase of our system and of the performance and completion of milestones under our customer and collaboration agreements. As a result, our revenue for any particular period can be difficult to forecast, especially in light of the challenging and inconsistent global macroeconomic environment and related market uncertainty. Our revenue may grow at a slower rate than in past periods or even decline on a year-over-year basis. For example, ~~under~~in the third quarter of 2022, our active collaboration agreement with Ginkgo ~~Bioworks, or Ginkgo,~~wound down prior to the anticipated contract end date, as the negotiations regarding potential changes to such agreement provides that we are eligible to receive certain minimum annual payments from Ginkgo for purchases and services, as well as milestone payments upon the achievement of certain development and regulatory milestones resulting from the use of certain of our proprietary workflows. However, we are unable to predict with precision whether and the extent to which Ginkgo will exceed the minimum annual payments under our agreement, or the timing of the achievement of any milestones under the agreement, if achieved at all, even though we maintain discussions on such matters.failed. In some cases, the timing and likelihood of payments to us under ~~these~~ agreements with customers is dependent on our customers’ successful utilization of our products and workflows, which is outside of our control. In the near term, we expect revenue from our strategic partnerships and services engagements to decline; more generally, our operating results could vary materially from quarter to quarter from our forecasts due to the foregoing uncertainties.

We may face risks in connection with past, existing and future collaborations with respect to the development, manufacture and commercialization of our products and workflows.

We face a number of risks in connection with our past, current and future collaborations and partnerships. Our partnerships and collaboration agreements are subject to termination under various circumstances. For example, in the third quarter of 2022, our active collaboration agreement with Ginkgo wound down prior to the anticipated contract end date, as negotiations regarding potential changes to such agreement failed. Our partners and collaborators may change the focus of their development efforts or may have insufficient resources to effectively assist in the development of our products or workflows. Any future partnerships or collaboration agreements may have the effect of limiting the areas of research and development that we may pursue, either alone or in collaboration with third parties. Further, disagreements with partners or collaborators might cause delays, might result in litigation or arbitration, or might result in termination of the research, development or commercialization of our products and workflows. Any such disagreements would divert management attention and resources and be time-consuming and costly.

Misconduct, non-compliance with laws, regulations, contractual arrangements and internal policies and unauthorized actions taken purportedly on our behalf by our employees, consultants, distributors, commercial partners, agents and vendors or other third-parties exposes us to risk.

We are exposed to the risk of fraud, misconduct or unauthorized conduct by our employees, consultants, distributors, commercial partners, agents and vendors or other third-parties. Misconduct or fraudulent acts by these parties could include intentional failures to comply with the applicable laws and regulations in the United States and abroad, including but not limited to reporting financial information or data accurately or disclosing unauthorized activities to us. Such fraudulent acts or misconduct could result in legal or regulatory sanctions and

cause serious harm to our reputation, as well as impact our ongoing business relationships. Unauthorized conduct could include intentional or unintentional failures by these parties to comply with contractual terms, policies, procedures and internal controls. The result of such unauthorized conduct could be difficult and costly to unwind or otherwise address. It is not always possible and we are not always able to identify and deter such fraud, misconduct or unauthorized conduct by such parties, and other precautions we take to detect and prevent such activities are not always effective in controlling risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws, regulations, contractual arrangements, policies, procedures or controls. If any actions are instituted against us for such fraud, misconduct or unauthorized conduct, and we are not successful in defending ourselves or asserting our rights, such actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.

The risk factors included in our Annual Report and in this Quarterly Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer.

Except as provided above, there have been no material changes to the risk factors set forth in the Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Sale of Unregistered Securities

There were no unregistered sales of the Company's equity securities during the three months ended ~~June~~September 30, 2022.

Use of Proceeds from our IPO

On July 21, 2020, we closed our IPO, in which we issued and sold 9,315,000 shares of our common stock, including the full exercise of the underwriters’ over-allotment option, at a public offering price of $22.00 per share for aggregate offering proceeds of $204.9 million. All of the shares of common stock issued and sold in the

offering were registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-1 (File No. 333-239487), which was declared effective by the SEC on July 16, 2020.

Cash used since the IPO is described elsewhere in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our periodic reports filed with the SEC. As of the date of this filing, there has been no material change in the planned use of proceeds from our IPO as described in the final prospectus for our IPO dated July 16, 2020 filed with the SEC on July 17, 2020.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

4142

Item 6. Exhibits.

The following exhibits are filed with this Quarterly Report on Form 10-Q:

Incorporated by Reference
Exhibit Number Exhibit Title Form File No. Exhibit Filing Date Filed Herewith
3.1
Amended and Restated Certificate of Incorporation of Berkeley Lights, Inc.
8-K 001-39388 3.1 7/21/2020
3.2
Amended and Restated Bylaws of Berkeley Lights, Inc.
8-K 001-39388 3.2 7/21/2020
10.5
Employment Offer Letter by and between Berkeley Lights , Inc. and Mehul Joshi
X
31.1
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
31.2
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
32.1*
Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
32.2*
Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101.INS XBRL Instance Document. X
101.SCH XBRL Taxonomy Extension Schema Document. X
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document X
101.DEF XBRL Taxonomy Extension Definition Linkbase Document. X
101.LAB XBRL Taxonomy Extension Label Linkbase Document. X
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. X
104 Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101 X

Incorporated by Reference

Exhibit Number

Exhibit Title

Form

File No.

Exhibit

Filing Date

Filed Herewith

3.1

Amended and Restated Certificate of Incorporation of Berkeley Lights, Inc.

8-K

001-39388

3.1

7/21/2020

3.2

Amended and Restated Bylaws of Berkeley Lights, Inc.

8-K

001-39388

3.2

7/21/2020

10.1

Employment Offer Letter by and between Berkeley Lights, Inc. and Mehul Joshi

10-Q

001-39388

10.5

8/9/2022

10.2

Employment Offer Letter by and between Berkeley Lights, Inc. and Scott Chaplin

31.1

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*

Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

104

Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101

*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in such filings

4243

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.

Berkeley Lights, Inc.


Date: ~~August 9,~~November 8, 2022	By:	/s/ J. Paul McClaskey
		J. Paul McClaskey Chief Accounting Officer (Authorized Signatory and Chief Accounting Officer)

4344


	Three Months Ended June 30, 2022
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at March 31, 2022	67,820,115	$	4	$	478,231	$	(285,034)	$	—	$	193,201
Shares issued in connection with:
Exercise of stock options	181,013	—		354		—		—		354
Vesting of restricted stock units	272,804	—		—		—		—		—

Stock-based compensation	—	—		6,627		—		—		6,627
Other comprehensive loss	—	—		—		—		(19)		(19)
Net loss	—	—		—		(25,747)		—		(25,747)
Balances at June 30, 2022	68,273,932	$	4	$	485,212	$	(310,781)	$	(19)	$	174,416


	Three Months Ended June 30, 2021
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(In thousands, except share data)	Shares	Amount
Balances at March 31, 2021	66,384,736	$	4	$	449,681	$	(207,319)	$	—	$	242,366
Shares issued in connection with:
Exercise of stock options	644,610	—		1,985		—		—		1,985
Vesting of restricted stock units	14,191	—		—		—		—		—
Stock-based compensation	—	—		5,642		—		—		5,642

Net loss	—	—		—		(18,154)		—		(18,154)
Balances at June 30, 2021	67,043,537	$	4	$	457,308	$	(225,473)	$	—	$	231,839


	As of June 30, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper	$	5,395	$	—	$	(8)	$	5,387
U.S. government securities	3,982		—		(8)		3,974
Total	$	9,377	$	—	$	(16)	$	9,361